

8.8 Hz, 1 H, W2), 7.31 (s, 1 H, 1b), 7.15 (d, $J = 8.6$ Hz, 1 H, 1f), 7.06 (d, $J = 8.7$ Hz, 1 H, 1e), 6.93 (d, $J = 8.3$ Hz, 2 H, 2b and 2f), 6.85 (d, $J = 8.2$ Hz, 1 H, W1), 6.70 (t, $J = 2.1$ Hz, 1 H, 3d), 6.61 (s, 1 H, 3b), 6.60 (d, $J = 8.5$ Hz, 2 H, 2c and 2e), 6.22 (s, 1 H, 3f), 5.31 (d, $J = 7$ Hz, 1 H, X3), 5.18 (d, $J = 8.2$ Hz, 1 H, X1), 4.63 (ddd, $J = 10.0, 8.8, 5.2$ Hz, 1 H, X2), 4.01 (m, 2 H, $-\text{OCH}_2\text{CH}_3$), 3.76 (s, 3 H, OCH_3), 3.74 (s, 3 H, OCH_3), 2.84 (dd, $J = 13.6, 10.0$ Hz, 1 H, Z2), 2.55 (dd, $J = 13.6, 5.2$ Hz, 1 H, Z2'), 1.37 (s, 9 H, Boc), 1.08 (t, $J = 7.0$ Hz, CH_2CH_3). ^{13}C NMR (DMSO- d_6 , 50 MHz): δ 169.69, 169.51, 168.89, 160.60, 159.05, 155.72, 154.32, 149.90, 142.75, 140.84, 131.80, 129.90, 127.48, 121.31, 120.28, 114.97, 112.96, 108.56, 103.51, 102.69, 78.37, 61.31, 55.84, 55.72, 55.49, 53.44, 36.81, 28.13, 13.81. IR (KBr): ν_{max} 3500-3200, 3000, 1740, 1695, 1670, 1630, 1620, 1590, 1520, 1375, 1275, 1142, 1130, 1060, 1040, 870, 845, 690 cm^{-1} . MS (EI): m/e 549 (fragment ion, $\text{M}^+ - \text{Boc}$).

Anal. Calcd for $\text{C}_{34}\text{H}_{39}\text{N}_3\text{O}_{10}$: C, 62.85; H, 6.05; N, 6.47. Found: C, 62.80; H, 6.00; N, 6.49.

Acknowledgment. We thank Dr. Rama Rao for his keen interest and encouragement. We also thank Dr. J.

A. R. P. Sharma for helping us to draw the ball and stick representation of 2.

Registry No. 1, 61036-62-2; 2, 143145-51-1; 3, 99-10-5; 4, 2150-44-9; 5, 19520-74-2; 6, 129866-90-6; 7, 143145-52-2; 8, 143145-53-3; 9, 143145-54-4; 10, 143145-55-5; 11, 143145-56-6; 12, 143145-57-7; 13, 143145-58-8; 14, 143145-58-8; 15, 143145-60-2; 16, 143145-61-3; 17, 143145-62-4; 18, 143145-63-5; 19, 143145-64-6; 20, 143145-65-7; 21, 143234-79-1; 22, 143145-66-8; 23, 143145-67-9; 24, 143145-68-0; 25, 143171-01-1; 26, 143145-69-1; 27, 143145-70-4; 28, 143171-02-2; Z-D-Tyr-OH, 20989-17-7; 4-MeOC₆H₄CHO, 123-11-5; HS(CH₂)₃SH, 109-80-8; Me₃SiCH₂CH₂OH, 2916-68-9; (R)-H₂NCH(Ph)CH₂OH, 56613-80-0; (S)-H₂NCH(Ph)CH₂OH, 64205-12-5.

Supplementary Material Available: ^1H NMR spectra of 4-9 and 12 and both ^1H and ^{13}C NMR spectra of 10, 14, 17, 18, 22, 25, and 2 (21 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

Aluminoxy Acetals from α -Amino Esters: Chirality Transfer via Sequential Addition of Hydride and C-Nucleophiles. 2-Amino Alcohols and Sphingosines[†]

Robin Polt,* Matt A. Peterson, and Lynn DeYoung[†]

Department of Chemistry, University of Arizona, Tucson, Arizona 85721

Received February 26, 1992 (Revised Manuscript Received July 6, 1992)

The reaction of α -imino esters (O'Donnell's Schiff bases) with aluminum hydrides to produce acetal-like intermediates and subsequent reaction with carbon nucleophiles has been studied. Treatment of optically pure imine-protected amino esters with $i\text{Bu}_2\text{AlH}$ or $i\text{Bu}_2\text{AlH}\cdot\text{Bu}_3\text{Al}$, followed by RMgX or RLi provided *threo*-2-amino alcohols in high yield (73-85%) and excellent "*syn*" stereoselectivity (8:1 to >20:1, *threo* or *like* product preferred). Use of nonpolar solvents (CH_2Cl_2 -hexane) provided the highest stereoselectivities. Use of the less-reactive $i\text{Bu}_2\text{AlH}\cdot i\text{Bu}_3\text{Al}$ complex lowered the amount of undesired primary alcohol products observed. Thermally labile aluminoxy acetal intermediates were observed by ^1H NMR and were trapped with *N*-(trimethylsilyl)imidazole to produce relatively stable monosilyl acetals (mixed acetals). Alanine-derived Schiff bases 2a-e showed a correlation between the steric bulk of the ester and *threo* selectivity. The presence of THF reduced this correlation, suggesting the C-nucleophile addition involves a Lewis acid-assisted $\text{S}_{\text{N}}2$ -like displacement of the aluminoxy acetal or displacement of a tight-ion pair. In addition to the synthesis of optically pure aryethanolamines 6a-d from representative amino acids, *threo*-sphingosines 8a-d were synthesized from L-serine-derived Schiff base 4b, and 1-deoxy-*threo*-sphingosines 9a-d were synthesized from L-alanine in a similar fashion. Experimental details are provided.

Introduction

As part of our program for the development of methods for the synthesis of complex carbohydrates, we became interested in the synthesis of sphingosines (Scheme I). Sphingosines² and their derivatives (cf. ceramides, cerebrosides, glycosphingolipids, gangliosides, and their lyso derivatives)³ are known to play diverse roles in many biological systems. Glycosphingolipids influence cell metabolism in vertebrates, as well as in lower organisms (fungi).^{7c} Galactosyl ceramide has recently been shown to be a receptor for HIV binding in cells lacking the CD4 receptor.^{4e} Analogs of glycosphingolipids have been the

subject of much interest as inhibitors of influenza-induced sialidase activity, as well as endoglycoceramidase inhib-

(1) For a preliminary account, see: Polt, R.; Peterson, M. A. *Tetrahedron Lett.* 1990, 31, 4985.


(2) (a) Klenk, E.; Diebold, W. *Hoppe-Seyler's Z. Physiol. Chem.* 1931, 198, 25. (b) Carter, H. E.; Norris, W. P.; Glick, F. J.; Phillips, G. E.; Harris, R. J. *Biol. Chem.* 1947, 170, 269. (c) Shapiro, D.; Segal, K.; Flowers, H. M. *J. Am. Chem. Soc.* 1958, 80, 1194. (d) Reist, E. J.; Christie, P. H. *J. Org. Chem.* 1970, 35, 4127.

(3) For lead references on the synthesis of gangliosides, see: (a) Ito, Y.; Numata, M.; Sugimoto, M.; Ogawa, T. *J. Am. Chem. Soc.* 1989, 111, 8508. (b) Nicolaou, K. C.; Caulfield, T. J.; Kataoka, H.; Stylianides, N. A. *J. Am. Chem. Soc.* 1990, 112, 3693. (c) Kameyama, A.; Ishida, H.; Kiso, M.; Hasegawa, A. *Carbohydr. Res.* 1991, 209, C1. For recent reviews of glycolipid synthesis, see: (d) Gigg, J.; Gigg, R. *Top. Curr. Chem.* 1990, 154, 77. (e) Paulsen, H. *Angew. Chem., Int. Ed. Engl.* 1990, 29, 823. (f) Kunz, H. *Angew. Chem., Int. Ed. Engl.* 1987, 26, 294-308. (g) Schmidt, R. R. *Angew. Chem., Int. Ed. Engl.* 1986, 25, 212-235. (h) Garg, H. G.; Jeanloz, R. W. *Adv. Carbohydr. Chem. Biochem.* 1985, 43, 135-201. (i) Paulsen, H. *Angew. Chem., Int. Ed. Engl.* 1982, 21, 155-224.


[†] This paper is dedicated to Professor Gilbert J. Stork on the occasion of his 70th birthday.

[†] University of Arizona Undergraduate Biology Research Program participant, funded in part by a grant from the Howard Hughes Medical Institute.

Scheme I
Antigen Le_x — Nicolaou, et al.^{3b}



Scheme II^a



^a (a) 2 *i*Bu₂AlH/CH₂Cl₂/-78 °C; (a') *i*Bu₂AlH-*i*Bu₂Al/CH₂Cl₂/-78 °C; (b) 2.5 *i*Bu₂AlH/CH₂Cl₂/0 °C/4 h; (c) 5 *i*Bu₂AlH/CH₂Cl₂/rt/16 h; (d) 3PhMgBr/Et₂O/rt/1 h; (e) 3PhMgBr/Et₂O/-78 °C → rt; (f) TMS-imidazole.

itors.^{4a} Perhaps most importantly, sphingosines and their derivatives have been shown to influence the transfer of

information between developing vertebrate cells.⁴


While several methods for the synthesis of optically pure sphingosines have been utilized,⁷ one of the most straightforward approaches is based on the use of L-serine as a source of chirality. In this approach, suitably protected L-serine esters are converted to their corresponding α -amino aldehyde and reacted with various carbon nucleophiles. While optically active α -amino aldehydes derived from their corresponding α -amino acids are potentially useful in a number of synthetic contexts,⁸ these

(6) (a) Hannun, Y. A.; Bell, R. P. *Science* 1987, 235, 670. (b) Hannun, Y. A.; Loomis, C. R.; Merrill, A. H.; Bell, R. M. *J. Biol. Chem.* 1986, 261, 12604. (c) Hannun, Y. A.; Greenberg, C. S.; Bell, R. M. *J. Biol. Chem.* 1987, 262, 13620. (d) Lambeth, J. D.; Burnham, D. N.; Tyagi, S. R. *J. Biol. Chem.* 1988, 263, 3818. (e) Wilson, E.; Wang, E.; Mullins, R. E.; Uhlinger, D. J.; Liotta, D. C.; Lambeth, J. D.; Merrill, A. H. *J. Biol. Chem.* 1988, 263, 9304. (f) Slife, C. W.; Wang, E.; Hunter, R.; Wang, S.; Burgess, C.; Liotta, D. C.; Merrill, A. H. *J. Biol. Chem.* 1989, 264, 10371. (g) Robertson, D. G.; DiGirolamo, M.; Merrill, A. H.; Lambeth, J. D. *J. Biol. Chem.* 1989, 264, 6773. (h) Manev, H.; Favaron, M.; Vicini, S.; Guidotti, A.; Costa, E. *J. Pharm. Exp. Ther.* 1990, 252, 419. (i) Morrison, W. J.; Offner, H.; Vandenberg, A. A. *Life Sci.* 1989, 45, 1219. (j) Chan, K. F. *J. J. Biol. Chem.* 1987, 262, 5248. (k) Chan, K. F. *J. J. Biol. Chem.* 1988, 263, 568. (l) Chan, K. F. *J. J. Biol. Chem.* 1989, 264, 18632. (m) Yates, A. J.; Walters, J. D.; Wood, C. L.; Johnson, J. D. *J. Neurochem.* 1989, 53, 162. (n) Kozikowski, A. P.; Wu, J.-P. *Tetrahedron Lett.* 1990, 31, 4309.

(7) Serine aldehyde + nucleophile approach to sphingosines: (a) Newman, H. *J. Am. Chem. Soc.* 1973, 95, 4098. (b) Tkaczuk, P.; Thornton, E. R. *J. Org. Chem.* 1981, 46, 4393. (c) Mori, K.; Funaki, Y. *Tetrahedron* 1985, 41, 2379. (d) Boutin, R. H.; Rapoport, H. *J. Org. Chem.* 1986, 51, 5320. (e) Garner, P.; Park, J. M.; Malecki, E. *J. Org. Chem.* 1988, 53, 4396. (f) Herold, P. *Helv. Chim. Acta* 1988, 71, 354. (g) Nimkar, S.; Menaldino, D.; Merrill, A. H.; Liotta, D. *Tetrahedron Lett.* 1988, 29, 3037. Also see ref 6n. Sharpless epoxidation/iodolactonization approaches: (h) Roush, W. R.; Adam, M. A. *J. Org. Chem.* 1985, 50, 3752. (i) Cardillo, G.; Orena, M.; Sandri, S.; Tomasini, C. *Tetrahedron* 1986, 42, 917. (j) Julina, R.; Herzig, T.; Bernet, B.; Vasella, A. *Helv. Chim. Acta* 1986, 69, 368. Glycine anion + electrophile approach: (k) Grob, C. A.; Gadiant, F. *Helv. Chim. Acta* 1957, 40, 1145. (l) Schmidt, R. R.; Kläger, R. *Angew. Chem., Int. Ed. Engl.* 1982, 21, 210. (m) Nicolaou, K. C.; Caulfield, T.; Kataoka, C. H.; Kumazawa, T. *J. Am. Chem. Soc.* 1988, 110, 7910. (n) Ito, Y.; Sawamura, M.; Hayashi, T. *Tetrahedron Lett.* 1988, 29, 239. (o) Singh, N. P.; Giannis, A.; Henk, E.; Kolter, T.; Sandhoff, K.; Schmidt, R. R. *J. Carbohydr. Chem.* 1990, 9, 543. (p) Groth, U.; Schöllkopf, U.; Tiller, T. *Tetrahedron* 1991, 47, 2835. Carbohydrate-based approaches: (q) Gigg, J.; Gigg, R.; Warren, C. D. *J. Chem. Soc. C* 1966, 1872. (r) Gigg, J.; Gigg, R. *J. Chem. Soc. C* 1966, 1876. (s) Reference 2d. (t) Obayashi, M.; Schlosser, M. *Chem. Lett.* 1985, 1715. (u) Schmidt, R. R.; Zimmermann, P. *Tetrahedron Lett.* 1986, 27, 481. (v) Koike, K.; Numata, M.; Sugimoto, M.; Nakahara, Y.; Ogawa, T. *Carbohydr. Res.* 1986, 158, 113. Diels-Alder approach: (w) Garigipati, R. S.; Weinreb, S. M. *J. Am. Chem. Soc.* 1983, 105, 4499.


(4) (a) Hasegawa, A.; Morita, M.; Kojima, Y.; Ishida, H.; Kiso, M. *Carbohydr. Res.* 1991, 214, 43. For reviews of some of the important known roles of sphingosines in intercellular interactions, see: (b) Hakomori, S. *Handbook of Lipid Research, Vol. 3, Sphingolipid Biochemistry*; Kanfer, J. N., Hakomori, S., Eds.; Plenum Press: New York, 1983; Chapter 4, pp 327-373. (c) *Gangliosides and Modulation of Neuronal Functions*; Rahmann, H., Ed.; Springer-Verlag: Berlin, 1987. (d) Margolis, R. K.; Margolis, R. U. *Neurobiology of Glycoconjugates*; Plenum Press: New York, 1989. (e) Harouse, J. M.; Bhat, S.; Spitalnik, S.; Laughlin, M.; Stefano, K.; Silberberg, F.; Gonzalez-Scarano, F. *Science* 1991, 253, 320.

(5) It is now accepted that the tumor-promoting phorbol esters and ingenols activate protein kinase C (PKC) by mimicking the actions of diacylglycerols (DAG, the normal messenger involved in PKC activation). (a) Nishizuka, Y. *Nature (London)* 1984, 308, 693. (b) *Naturally Occurring Phorbol Esters*; Evans, F. J., Ed.; CRC Press: Boca Raton, FL, 1986. (c) Wender, P. A.; Lee, H. Y.; Wilhelm, R. S.; Williams, P. D. *J. Am. Chem. Soc.* 1989, 111, 8954. (d) Wender, P. A.; Koehler, K. F.; Sharkey, N. A.; Dell Aquila, M. L.; Blumberg, P. M. *Proc. Natl. Acad. Sci. U.S.A.* 1986, 83, 4214. (e) Kozikowski, A. P.; Sato, K.; Basu, A.; Lazo, J. S. *J. Am. Chem. Soc.* 1989, 111, 6228. Sphingosines, on the other hand, deactivate PKC, probably by binding to the same DAG binding site.^{6a-b} Sphingosines have also been shown to affect other, less well characterized kinases.^{6l-m}

Scheme III^a

^a (a) 2 equiv of $i\text{Bu}_2\text{AlH}/\text{CH}_2\text{Cl}_2/-78\text{ }^\circ\text{C}$; (a') 1 equiv of $i\text{Bu}_2\text{AlH}\cdot\text{Al}i\text{Bu}_3/\text{CH}_2\text{Cl}_2/-78\text{ }^\circ\text{C}$; (b) 3 equiv of $\text{PhMgBr}/\text{Et}_2\text{O}/-78\text{ }^\circ\text{C} \rightarrow 0\text{ }^\circ\text{C}$; (c) H_3O^+ . [†]Yield using method a'. **threo/erythro* ratio by NMR.

Scheme IV



methods often suffer from configurational instability (enolization) under a variety of reaction conditions.⁹ In addition, stereoselectivities in these reactions are often modest at best.^{6n,7a-g,11}

(8) The synthesis of adrenergic drugs based on the 1-arylphenethylamine structure is one example: (a) Fujita, M.; Hiyama, T. *J. Am. Chem. Soc.* 1984, 106, 4629. (b) Claremon, D. A.; Lumma, P. K.; Phillips, B. T. *J. Am. Chem. Soc.* 1986, 108, 8265. Another example is the synthesis of statine, conformationally restrained amino acids, and peptide isosteres: (c) Rich, D. H.; Sun, E. T.; Bopari, A. S. *J. Org. Chem.* 1978, 43, 3624. (d) Danishefsky, S.; Kobayashi, S.; Kerwin, J. F. *J. Org. Chem.* 1982, 47, 1981. (e) Woo, P. W. K. *Tetrahedron Lett.* 1985, 26, 2973. (f) Kogen, H.; Nishi, T. *J. Chem. Soc., Chem. Commun.* 1987, 311. (g) Joun, P.; Castro, B. *J. Chem. Soc., Perkin Trans. 1* 1987, 1177. (h) Andrew, R. G.; Conrow, R. E.; Elliott, J. D.; Johnson, W. S.; Ramezani, S. *Tetrahedron Lett.* 1987, 28, 6535. (i) de Frutos, M. P.; Fernández, D.; Fernández-Alvarez, E.; Bernabé, M.; *Tetrahedron Lett.* 1991, 32, 541. (j) Davidsen, S. K.; Chu-Moyer, M. Y. *J. Org. Chem.* 1989, 54, 5558. (k) Kiyooka, S.; Nakano, M.; Shiota, F.; Fujiyama, R. *J. Org. Chem.* 1989, 54, 5409. (l) Mikami, K.; Kaneko, M.; Loh, T. P.; Terada, M.; Nakai, T. *Tetrahedron Lett.* 1990, 31, 3909. (m) Kano, S.; Yokomatsu, T.; Shibuya, S. *Tetrahedron Lett.* 1991, 32, 233. (n) DeCamp, A. E.; Kawaguchi, A. T.; Volante, R. P.; Shinkai, I. *Tetrahedron Lett.* 1991, 32, 1867. (o) Hanson, G. J.; Lindberg, T. *J. Org. Chem.* 1985, 50, 5399. (p) Ibuka, T.; Habashita, H.; Otake, A.; Fujii, N.; Oguchi, Y.; Uyehara, T.; Yamamoto, Y. *J. Org. Chem.* 1991, 56, 4370. (q) Denis, J.-N.; Correa, A.; Greene, A. E. *J. Org. Chem.* 1991, 56, 6939. Other natural products: (r) Stork, G.; Nakamura, E. *J. Am. Chem. Soc.* 1983, 105, 5510. (s) Trost, B. M.; Ohmori, M.; Boyd, S. A.; Okawa, H.; Brickner, S. J. *J. Am. Chem. Soc.* 1989, 111, 8281. (t) Reetz, M. T.; Drewes, M. W.; Schmitz, A. *Angew. Chem., Int. Ed. Engl.* 1987, 26, 1141.

(9) Racemization of α -amino aldehydes is a problem: (a) Fehrentz, J. A.; Castro, B. *Synthesis* 1983, 676. (b) Rittle, K. E.; Homnick, C. F.; Ponticello, G. S.; Evans, B. E. *J. Org. Chem.* 1982, 47, 3016. (c) See Rapoport, ref 10.

(10) Lubell, W. D.; Rapoport, H. *J. Am. Chem. Soc.* 1988, 110, 7447.

(11) Jurczak, J.; Golebiowski, A. *Chem. Rev.* 1989, 89, 149.

(12) (a) Grandbois, E. R.; Howard, S. I.; Morrison, J. D. In *Asymmetric Synthesis*; Morrison, J. D., Ed.; Academic Press: New York, 1983; Vol. 2, Chapter 3, pp 71–90. (b) Evans, D. A. *Science* 1988, 240, 420. (c) Oishi, T.; Nakata, T. *Acc. Chem. Res.* 1984, 17, 338. (d) Noyori, R.; Takaya, H. *Acc. Chem. Res.* 1990, 23, 345. Also: (e) Maibaum, J.; Rich, D. H. *J. Org. Chem.* 1988, 53, 869. (f) Schuda, P. F.; Greenlee, W. J. *J. Org. Chem.* 1988, 53, 873.

(13) (a) Maurer, P. J.; Takahata, H.; Rapoport, H. *J. Am. Chem. Soc.* 1984, 106, 1095. (b) Knudsen, C. G.; Rapoport, H. *J. Org. Chem.* 1983, 48, 2260. (c) Buckley, T. F.; Rapoport, H. *J. Am. Chem. Soc.* 1981, 103, 6157.

(14) (a) Masamune, S.; Bates, G. S.; Corcoran, J. W. *Angew. Chem., Int. Ed. Engl.* 1977, 16, 585. (b) Mukaiyama, T.; Araki, M.; Takei, H. *J. Am. Chem. Soc.* 1973, 95, 4763. (c) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* 1981, 22, 3815. (d) Danheiser, R. L.; Morin, J. M.; Salaski, E. *J. Am. Chem. Soc.* 1985, 107, 8066.

Newman^{7a} was the first to attempt the stereoselective addition of carbon nucleophiles to a protected serine aldehyde derivative. Since then, there have been a number of syntheses based on this approach. The most notable and widely used example is that developed by Garner^{7c–e} which uses a BOC-protected oxazolidine to protect both the hydroxyl and amino functionality. Garner's method is attractive in that it avoids the racemization problems typically associated with this type of reaction. Another widely applicable approach to the protection of α -amino aldehydes which avoids the problem of enolization has been used by Rapoport, and it employs the 9-phenylfluorenyl blocking group for the amine.^{10,11}

It is clear that new diastereoselective methods for the synthesis of β -amino alcohols from α -amino acid derivatives which are more configurationally stable than α -amino aldehydes would be useful. Studies performed in our laboratory have revealed that sequential treatment of O'Donnell's Schiff base esters¹⁶ with $i\text{Bu}_2\text{AlH}$ or

(15) (a) Meyers, A. I.; Comins, D. L. *Tetrahedron Lett.* 1978, 5179. (b) Comins, D. L.; Herrick, J. *J. Tetrahedron Lett.* 1984, 25, 1321. (c) Burke, S. D.; Deaton, D. N.; Olsen, R. J.; Armistead, D. M.; Blough, B. E. *Tetrahedron Lett.* 1987, 28, 3905. (d) Jackson, W. R.; Jacobs, H. A.; Mathews, B. R.; Jayatilake, G. S. *Tetrahedron Lett.* 1990, 31, 1447. (e) Bolis, G.; Fung, A. K. L.; Greer, J.; Kleinert, H. D.; Marcotte, P. A.; Perun, T. J.; Plattner, J. J.; Stein, H. H. *J. Med. Chem.* 1987, 30, 1729. (f) Kano, S.; Yuasa, Y.; Yokomatsu, T.; Shibuya, S. *Chem. Pharm. Bull.* 1989, 37, 2867.

(16) (a) O'Donnell, M. J.; Polt, R. L. *J. Org. Chem.* 1982, 47, 2663. For other uses of benzophenone Schiff bases, see: (b) O'Donnell, M. J.; Bennett, W. D.; Wu, S. *J. Am. Chem. Soc.* 1989, 111, 2353 and reference 7 therein.

(17) (a) Kovacs, G.; Galambos, G.; Juvancz, Z. *Synthesis* 1977, 171. (b) Kim, S.; Ahn, K. H. *J. Org. Chem.* 1984, 49, 1717.

(18) Zakharin, L. I.; Khorlina, I. M. *Tetrahedron Lett.* 1962, 619.

(19) (a) 1-Phenyl-2-aminoethanol: Pouchert, C. J. *Aldrich Handbook of NMR Spectra*; Aldrich Chemical Co.: Milwaukee, WI, 1983; Vol. 1, 1079A. (b) (1*S*,2*S*)-(+)-2-Amino-1-phenyl-1-propanol: Baudet, M.; Gelbcke, M. *Anal. Lett.* 1979, 12B, 325. The (1*R*,2*R*)-(-)-isomer is available from Aldrich Chemical Co. as the HCl salt. (c) (1*S*,2*S*)-(+)-2-Amino-1,3-diphenyl-1-propanol: Marcot, B.; Rabaron, A.; Viel, C.; Bellec, C.; Deswarte, S.; Maitte, P. *Can. J. Chem.* 1981, 59, 1224. (d) Identical with (1*S*,2*S*)-(+)-2-amino-1-phenyl-1,3-propanediol from Aldrich Chemical Co.

$i\text{Bu}_3\text{Al}\cdot i\text{Bu}_2\text{AlH}$ and PhMgBr provide the corresponding α -amino alcohols in excellent chemical and stereochemical yield. Stereoselectivities were at least 8:1 in favor of the *threo* (*syn* or *like*) isomer when either $i\text{Bu}_2\text{AlH}$ or $i\text{Bu}_3\text{Al}\cdot i\text{Bu}_2\text{AlH}$ were used as hydride source. Chemical yields were markedly superior for the $i\text{Bu}_3\text{Al}\cdot i\text{Bu}_2\text{AlH}/\text{PhMgBr}$ case. Stereoselectivities increased to greater than 15:1 were observed when alkyllithium reagents in hexane were substituted for the Grignard reagents. Since both hydride and Grignard or alkyllithium reagents were added to the reaction mixture at -78°C , the racemization problems associated with isolating the intermediate α -amino aldehyde have been avoided. Evidence obtained in this laboratory suggests that the α -amino aldehyde resulting from DIBAL reduction of the ester is *not* the reactive species. Instead, the thermally labile aluminoy acetal²⁴

generated by delivery of one hydride to the chelating imino ester is shown to be the reactive intermediate. This conclusion is supported by a study of the directing ability of bulky ester groups, as well as the low-temperature stability and trapping of the intermediate aluminoy acetals. Details of these experiments as well as the application of this methodology in the stereoselective synthesis of *threo*-sphingosines are presented.

***threo*-1-Arylethanolamines.** Preliminary experiments were performed with the commercially available Schiff base 1 to determine the reactivity of the imine moiety toward aluminum hydrides and Grignard reagents (Scheme II). The hindered imine bond proved to be remarkably stable toward $i\text{Bu}_2\text{AlH}$ in CH_2Cl_2 at -78°C and totally inert toward PhMgBr in Et_2O . At higher temperatures (e.g. rt) $i\text{Bu}_2\text{AlH}$ reduced the $\text{Ph}_2\text{C}=\text{N}$ group to $\text{Ph}_2\text{CH}-\text{NH}$, but only after the ester was completely reduced to the primary alcohol. In the absence of added PhMgBr , reduction to the aluminoy acetal¹⁸ was extremely slow, as indicated by the reaction with TMS-imidazole to provide the monosilyl acetal. Even after 30 h at -78°C , reduction of the chelating ester 1 was not complete in the absence of RLi or RMgX . Treatment of 1 with 2 equiv of $i\text{Bu}_2\text{AlH}$ in CH_2Cl_2 at -78°C for 1 h, followed by 3 equiv of PhMgBr in Et_2O , and warming to rt afforded the crystalline secondary alcohol 5a in 64% yield after aqueous workup. Thus, sequential addition of H^- followed by Ph^- to chelating Schiff base esters was shown to be plausible.

The diastereoselectivity of the reaction with $i\text{Bu}_2\text{AlH}$ and PhMgBr was examined using the Schiff base esters derived from L-alanine, 2b, L-phenylalanine, 3, and L-serine, 4b (Scheme III). It was possible to isolate either the protected β -amino alcohols 5a-d by quenching the reaction with NaHCO_3 or the known phenylethanolamines¹⁹ 6a-d by an acidic workup. In each case the reaction was found to be highly *threo* selective (Scheme III), the two byproducts consisting of the *erythro* isomer, and the primary alcohol from overreduction. The sense of the stereocontrol may be predicted by invoking the cyclic Cram chelate model²⁰ for initial hydride delivery to the ester, followed by subsequent inversion of the resulting aluminoy acetal by the incoming nucleophile (Scheme IV). The solvent dependence of the reaction supports this mechanistic interpretation (*vide infra*).

Solvent Effects and Mechanistic Implications. Two equivalents of $i\text{Bu}_2\text{AlH}$ were required for complete conversion of the Schiff base esters; use of lesser amounts resulted in recovery of unreacted starting material.²¹ Unfortunately, use of 2 equiv of $i\text{Bu}_2\text{AlH}$ resulted in the formation of significant amounts of overreduced primary alcohols. We reasoned that the additional H^- from the second equivalent of DIBAL was competing with Ph^- for the electrophilic aluminoy acetal (aldehyde) in the alkylation step. The simplest solution to the overreduction problem proved to be the use of a 1:1 mixture of $i\text{Bu}_2\text{AlH}$ and $i\text{Bu}_3\text{Al}$,²² which resulted in a 20–30% increase in yield of the desired product with a corresponding decrease in the amount of undesired primary imino alcohol. This reagent is stable for months in neat form or as a solution

(20) (a) Cram, D. J.; Kopecky, K. R. *J. Am. Chem. Soc.* 1959, 81, 1224. (b) Duhamel, P.; Duhamel, L.; Gralak, J. *Tetrahedron Lett.* 1972, 2329. (c) Still, W. C.; McDonald, J. H. *Tetrahedron Lett.* 1980, 1031. (d) Keck, G. E.; Boden, E. P. *Tetrahedron Lett.* 1984, 25, 265, 1879, 1883. (e) Reetz, M. T. *Angew. Chem., Int. Ed. Engl.* 1984, 23, 556. (f) Frye, S. V.; Eliel, E. L.; Cloux, R. *J. Am. Chem. Soc.* 1987, 109, 1862. (g) Nichols, M. A.; McPhail, A. T.; Arnett, E. M. *J. Am. Chem. Soc.* 1991, 113, 6222. As was pointed out by a very astute referee, probably the first conscious recognition of chelation control in the reduction of α -amino ketones was by Sorm et al. who reduced derivatives of dehydrochloramphenicol using Al-catalyzed Meerwein-Ponndorf-Verley reaction conditions. These reactions displayed either α - or β -chelation control, depending on the protecting groups: (h) Sicher, J.; Svoboda, M.; Hrdá, M.; Rudinger, J.; Sorm, F. *Collect. Czech. Chem. Commun.* 1953, 18, 487–499.

(21) Similar bidentate ligands are known to form planar, five-membered cyclic complexes of either 1:1 or 2:1 stoichiometry with aluminum alkyls. Examples of both 5-coordinate aluminum alkyls have been characterized by X-ray analysis, cf.: (a) van Vliet, M. R. P.; Buysingh, P.; van Koten, G.; Vrieze, K.; Kojic-Prodic, B.; Spek, A. L. *Organometallics* 1985, 4, 1701. (b) van Vliet, M. R. P.; van Koten, G.; de Keijser, M. S.; Vrieze, K. *Organometallics* 1987, 6, 1652. (c) Sierra, M. L.; de Mel, V. S. V.; Oliver, J. P. *Organometallics* 1989, 8, 2486, as well as 4-coordinate aluminum alkyls. Cf.: (d) van Vliet, M. R. P.; van Koten, G.; Rottevel, M. A.; Schrap, M.; Vrieze, K.; Kojic-Prodic, B.; Spek, A. L. *Organometallics* 1986, 5, 1389. (e) van der Steen, F. H.; van Mier, G. P. M.; Spek, A. L.; Kroon, J.; van Koten, G. *J. Am. Chem. Soc.* 1991, 113, 5742. (f) Amirkalili, S.; Hitchcock, P. B.; Smith, J. D.; Stamper, J. G. *J. Chem. Soc., Dalton Trans.* 1980, 2493. (g) Power, M. B.; Bott, S. G.; Atwood, J. L.; Barron, A. R. *J. Am. Chem. Soc.* 1990, 112, 3446. Such complexes have been invoked as important intermediates for carbonyl addition reactions: (h) Neumann, H. M.; Laemmle, J.; Ashby, E. C. *J. Am. Chem. Soc.* 1973, 95, 2597. (i) Ashby, E. C.; Laemmle, J. T. *Chem. Rev.* 1975, 75, 521. (j) Ashby, E. C.; Laemmle, J. T. *J. Org. Chem.* 1975, 40, 1469. (k) Ashby, E. C.; Smith, R. S. *J. Organomet. Chem.* 1982, 225, 71. (l) Maruoka, K.; Itoh, T.; Yamamoto, H. *J. Am. Chem. Soc.* 1985, 107, 4573. (m) Maruoka, K.; Itoh, T.; Sakuria, M.; Nanoshita, K.; Yamamoto, H. *J. Am. Chem. Soc.* 1988, 110, 3588. (n) Kai, Y.; Yasuoka, N.; Kasai, N.; Kakudo, M. *Bull. Chem. Soc. Jpn.* 1972, 45, 3403.


(22) Replacement of the second H^- equivalent with a bridging ligand such as Cl^- or PhO^- also suppressed the overreduction.^{21b} $\text{Et}_2\text{AlCl}\cdot i\text{Bu}_2\text{AlH}$ was formed by mixing equimolar amounts of DIBAL and Et_2AlCl , and $i\text{Bu}_2\text{AlOPh}\cdot i\text{Bu}_2\text{AlH}$ was formed by adding phenol to DIBAL, but these reagents were not stable enough for prolonged storage at room temperature.

(23) (a) Pasynkiewicz, S.; Sliwa, E. *J. Organomet. Chem.* 1965, 3, 121. (b) Eisch, J. J.; Rhee, S. G. *J. Organomet. Chem.* 1974, 42, C73. (c) Vestin, R.; Vestin, U.; Kowalewski, J. *Acta Chem. Scand.* A 1985, 39, 767. (d) Smith, M. B. *J. Organomet. Chem.* 1970, 22, 273. (e) Yamamoto, O.; Hayamizu, K.; Yanagisawa, M. *J. Organomet. Chem.* 1974, 73, 17.

(24) Mechanistic divergence ($\text{S}_{\text{N}}1$ vs $\text{S}_{\text{N}}2$) in the Lewis acid-catalyzed reaction of acetals with various nucleophiles has been noted: (a) Hosomi, A.; Ando, M.; Sakurai, H. *Chem. Lett.* 1986, 365. (b) Denmark, S. E.; Willson, T. M. *J. Am. Chem. Soc.* 1989, 111, 3475. (c) Mori, I.; Ishihara, K.; Flippin, L. A.; Nozaki, K.; Yamamoto, H.; Bartlett, P. A.; Heathcock, C. H. *J. Org. Chem.* 1990, 55, 6107. (d) Silverman, R.; Edington, C.; Elliott, J. D.; Johnson, W. S. *J. Org. Chem.* 1987, 52, 180. (e) Choi, V. M. F.; Elliott, J. D.; Johnson, W. S. *Tetrahedron Lett.* 1984, 25, 591. (f) Bartlett, P. A.; Johnson, W. S.; Elliott, J. D. *J. Am. Chem. Soc.* 1983, 105, 2088. (g) Burgess, L. E.; Meyers, A. I. *J. Am. Chem. Soc.* 1991, 113, 9858. (h) Kiyooka, S.; Shirouchi, M. *J. Org. Chem.* 1992, 57, 1. For kinetic data and arguments which support the notion of an $\text{S}_{\text{N}}2$ -like process, see: (i) Aymes, T. L.; Jencks, W. P. *J. Am. Chem. Soc.* 1989, 111, 7888. (j) Aymes, T. L.; Jencks, W. P. *J. Am. Chem. Soc.* 1989, 111, 7900.

(25) Vicinal coupling constants of cyclic carbamates have been used to assign the configuration of β -amino alcohols. Normally, $J_{\text{anti}} < J_{\text{syn}}$: (a) Seebach, D.; Beck, A. K.; Mukhopadhyay, T.; Thomas, E. *Helv. Chem. Acta* 1982, 65, 1101. (b) Kobayashi, S.; Isobe, T.; Ohono, W. *Tetrahedron Lett.* 1983, 24, 5079. But, these vicinal coupling values may be ambiguous, or even reversed when the substituents on the oxazolidinone ring are large: (c) Kano, S.; Yokomatsu, T.; Iwasawa, H.; Shibuya, S. *Chem. Lett.* 1987, 1531. Also see: refs 6n, 8k, 8l, and 8p.


Scheme V



in hexanes. $i\text{Bu}_2\text{AlH} \cdot i\text{Bu}_3\text{Al}$ in hexanes is the reagent (method a', Scheme II) now routinely used in the reduction/alkylation chemistry.

Whereas $i\text{Bu}_2\text{AlH}$ is known to be trimeric in noncoordinating solvents, the addition of $i\text{Bu}_3\text{Al}$ provides an equilibrium mixture of interconverting 2:1 trimer, 1:2 trimer, and 1:1 dimer²³ (Scheme V). The AlCH_2 resonances for this mixture in CD_2Cl_2 at -47°C appear at $+0.1589$, $+0.0815$, and $+0.0410$ ppm as doublets in the ^1H NMR. This mixture undergoes a profound and immediate change upon addition of 1 equiv of Schiff base 2a, shifting to a pair of 7-Hz doublets at -0.2117 and -0.2374 ppm.³⁸ This result suggests that the 1:1 dimer may form a complex with the bidentate Schiff base prior to reduction/alkylation. This interpretation is consistent with the increasing carbanionic character of the unsymmetrical "ate complex" B as the bidentate ligand supplies more electron density to the aluminum metal via σ -donation. The aluminoxy acetal forms much more slowly (72 h) at -78°C in the absence of added PhMgBr because "ate complex" B is much less reactive than the discrete "ate complex" A. Complexes such as A are known to be powerful reducing agents.¹⁷

Mechanistic studies reveal two important points concerning the reaction sequence: (1) although $i\text{Bu}_2\text{AlH}$ or $i\text{Bu}_3\text{Al} \cdot i\text{Bu}_2\text{AlH}$ alone will stereoselectively deliver hydride to the ester in CH_2Cl_2 or PhCH_3 at -78°C very slowly, the ate complex formed upon addition of RMgX or RLi is the kinetically active reducing agent,¹⁷ and (2) the subsequent alkylation step is extremely solvent dependent, and is best



^a (a') $i\text{Bu}_2\text{AlH} \cdot \text{Al}i\text{Bu}_3/\text{CH}_2\text{Cl}_2/-78^\circ\text{C}/72$ h; (a'') $i\text{Bu}_2\text{AlH} \cdot \text{PhLi}/\text{CH}_2\text{Cl}_2\text{-Et}_2\text{O}/-78^\circ\text{C}/2$ h; (b) TMS-imidazole/ $-78^\circ\text{C} \rightarrow 0^\circ\text{C}$.

characterized as a Lewis acid-assisted $\text{S}_{\text{N}}2$ process (tight ion-pair displacement).

To gain additional insight on the mechanism of this reaction, the intermediate aluminoxy acetal²⁶ derived from 2b was trapped with (trimethylsilyl)imidazole to provide the somewhat labile monosilyl acetal 7a (Scheme VI). In the absence of a nucleophile such as PhMgBr (c.f. "ate complex" B in Scheme V), reduction occurred very slowly,


(26) Racemic monosilyl acetals have been synthesized via Rh^1 -catalyzed hydrosilylation of esters: (a) Ojima, I.; Kumagai, M.; Nagai, Y. *J. Organomet. Chem.* 1976, 111, 43. They have also been generated in the reaction of esters with organometallics in the presence of Me_3SiCl : (b) Reetz, M. T.; Heimbach, H.; Schweltnus, K. *Tetrahedron Lett.* 1984, 25, 511. (c) Cooke, M. P. *J. Org. Chem.* 1986, 51, 951. Chiral, optically active monosilyl-acetals such as 7a and 7b have synthetic uses as electrophiles, as well. A study of this aspect is underway and will be the subject of a forthcoming communication.

but cleanly at $-78\text{ }^{\circ}\text{C}$ to afford a 6.5:1 mixture²⁷ of **7a** and **7b** after 72 h. Presumably, hydride reduction of imino ester **2b** proceeds through a cyclic Cram chelate to yield **7a** as the major product, although definitive proof of the configurations of **7a** or **7b** does not exist. If the reaction mixture is warmed to $-23\text{ }^{\circ}\text{C}$ for only 1 h and trapped with TMS-imidazole at $-78\text{ }^{\circ}\text{C}$ as before, complete reduction is observed and a 1:3 mixture of **7a** and **7b** is recovered. This suggests that equilibration of the initially formed "syn" aluminoxy acetal to the more stable "anti" form occurs at higher temperatures. This equilibration process can be compared to the "anomerization"³⁵ of carbohydrate derivatives via ion-pair mechanisms.

If a discrete aluminum "ate complex" was generated from $i\text{Bu}_2\text{AlH}\cdot i\text{Bu}_3\text{Al}$ and PhLi (cf. "ate complex" **A** in Scheme IV) and used to accomplish the reduction,¹⁷ a 2:1 mixture of the two isomeric monosilyl acetals **7a** and **7b** was formed in 2 h at $-78\text{ }^{\circ}\text{C}$. Clearly, the more reactive aluminate hydride donor was not as selective in the ester reduction as the more Lewis acidic 1:1 DIBAL-TRIBAL mixture. Very similar conditions (2 equiv of $i\text{Bu}_2\text{AlH}/3$ equiv of PhLi) also provided much poorer selectivity (nearly 2:1) in the alkylation reaction **2b** \rightarrow **5b**. Thus, we feel confident in stating that the initial hydride transfer step is stereochemically significant.

That the intermediate aluminoxy acetal is long lived at $-78\text{ }^{\circ}\text{C}$ and is indeed stable enough to be trapped with TMS-imidazole is not surprising in light of the examples of similar chelated tetrahedral intermediates that have been previously generated.^{12-15,26} For example, the long-standing problem of controlling the addition of metal alkyls to esters to provide ketones has been solved by stabilizing the intermediate tetrahedral structure by chelation. There are numerous methods for reducing the resultant ketones stereoselectively to provide the corresponding secondary alcohol.¹² Rapoport has demonstrated that the classical direct conversion of a free carboxylate to a ketone via alkylolithium addition can be effected with the proper choice of N-protection and by modification of the reaction conditions (use of $\text{RLi}\text{-RMgX}$ mixtures).¹³ Mukaiyama^{14a,b} and Weinreb^{14c} inter alia^{14d} have used chelation to stabilize the intermediate metaloxy acetals derived from the addition of an organometallic to thiopyridyl esters and *N*-methoxy-*N*-methylamides, respectively.

Meyers,^{15a} Comins,^{15b} and Burke,^{15c} inter alia,^{15d-f} have used chelation to stabilize intermediate metaloxy acetals in order to affect sequential, stereoselective delivery of a



^a (a) 1 equiv of $i\text{Bu}_2\text{AlH}\cdot i\text{Bu}_3\text{Al}/\text{CH}_2\text{Cl}_2/-78\text{ }^{\circ}\text{C}$; (b) 3 equiv of $\text{PhMgBr}/\text{Et}_2\text{O}/-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$; (b') 3 equiv of $\text{PhMgBr}/\text{Et}_2\text{O}\text{-THF}$ (1:1)/ $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$; (c) H_3O^+ .

hydride and/or organometallic reagents to provide secondary and tertiary alcohols directly from the carboxylic acid derivative. Mechanistically, this process has generally been viewed as a two-step process involving the elimination of alkoxide from the metaloxy acetal to produce a transient ketone or aldehyde,^{3p,15b,c} followed by addition of the second nucleophile, although Meyers' scheme suggests a displacement reaction.^{15a} Ibuka, Fujii, and Yamamoto^{8p} observed a highly (15:1) *threo*-selective reaction when *t*-Boc-protected methylalaninate was treated sequentially with DIBAL and $\text{H}_2\text{C}=\text{CHMgCl}$ (but not when treated with $\text{H}_2\text{C}=\text{CHMgBr}$). These authors presumed that an aluminum-chelated *t*-Boc-amino aldehyde (cyclic Cram transition state²⁰) was the intermediate responsible for the observed *threo* selectivity. Kiyooka^{24b} has invoked racemic aluminoxy-acetals as long-lived intermediates, but has not presented any stereochemical data.

There are two plausible mechanistic extremes for the conversion of the aluminoxy acetal intermediate to the observed *threo*-alcohol:²⁴ (1) an $\text{S}_{\text{N}}1$ -like mechanism involving *elimination* of an alkoxy group to generate an aldehyde intermediate which would suffer Cram-controlled addition by the Grignard, and (2) an $\text{S}_{\text{N}}2$ -like mechanism involving a *displacement* of the alkoxy group with inversion. In the presence of aluminum alkyls, one can imagine that a pathway intermediate between these $\text{S}_{\text{N}}1$ and $\text{S}_{\text{N}}2$ extremes is possible, e.g. a Lewis acid-assisted displacement.^{24c} Alternatively, one might wish to envision the intermediate pathway as a displacement of a tight ion-pair. If the $\text{S}_{\text{N}}1$ -like mechanism is operative, then the identity of the alkoxy group of the aluminoxy acetal should not affect the stereoselectivity of the alkylation reaction.

A series of alanine Schiff base esters **2a-e** were studied to determine the effect of increasing the steric bulk of the ester on the stereoselectivity of the $i\text{Bu}_2\text{AlH}\cdot i\text{Bu}_3\text{Al}/\text{PhMgBr}$ reaction (Scheme VII). The reaction mixtures were hydrolyzed directly to the phenylpropanolamines **5b** with 1 *N* HCl, washed with Et_2O , converted to the free bases, and analyzed by 250-MHz ¹H NMR without any further purification. When Et_2O was used as a cosolvent, there was a correlation between the bulk of the ester and the observed *threo* selectivity. As the bulk of the ester increased from Me (**2a**) to *t*-Bu (**2e**), the *threo* selectivity increased from 7.6:1 to 11:1. This provides evidence that the alkoxy group plays a role in the alkylation step of the reaction. If the intermediate in this reaction were an aldehyde, either free or aluminum-chelated,³⁰⁻³ one would expect the same stereoselectivity, regardless of the bulk

(27) Monosilyl acetal **7a** was isolated by flash chromatography on SiO_2 with 10% $\text{EtOAc}/\text{hexanes}$. (The corresponding mixed acetal derived from alanine methyl ester was not stable to SiO_2 chromatography.) ¹H NMR (250 MHz, CDCl_3): δ 7.65-7.10 (m, 10 H), 4.82 (d, $J = 6.3$ Hz, 1 H), 3.80-3.60 (m, 1 H), 3.50-3.30 (m, 2 H), 1.14 (t, $J = 7$ Hz, 3 H), 1.12 (d, $J = 6.4$ Hz, 3 H), 0.15 (s, 6 H), 0.09 (s, 3 H). $[\alpha]_{\text{D}} = +31.4$ ($c = 4.4$, CHCl_3). NOE studies were inconclusive. Monosilyl acetal **7b** could not be isolated in pure form, but was observed as mixtures with **7a**.

(28) Observed mp $87\text{-}89\text{ }^{\circ}\text{C}$ for **13** (lit. mp $86\text{-}87\text{ }^{\circ}\text{C}$ ^{7a} and $88.0\text{-}88.5\text{ }^{\circ}\text{C}$ ^{7b}). We were unable to dissolve enough of the amino diol **13** in either wet or dry CHCl_3 to observe a reliable optical rotation.^{7c} Observed $[\alpha]_{\text{D}} = +8.2^{\circ}$ ($c = 2.3/\text{CHCl}_3$) for **14** (lit. $[\alpha]_{\text{D}} 8.43^{\circ}$ (CHCl_3)^{7b} and 8.78° ($c = 1.2$, CHCl_3)^{7c}). See the Experimental Section for ¹H and ¹³C NMR data and MS data for **13** and **14**.

(29) Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* 1978, 43, 2923.

(30) (a) Szabó, L. Z.; Li, Y.; Polt, R. *Tetrahedron Lett.* 1991, 32, 585.

(b) Polt, R.; Szabó, L. Z.; Treiberg, J.; Li, Y.; Hruby, V. J., submitted to *J. Am. Chem. Soc.* (c) Szabó, L.; Polt, R., manuscript in preparation. (d) Polt, R.; Peterson, M. A., manuscript in preparation.

(31) Peterson, M. A.; Polt, R. *Synth. Commun.* 1992, 22, 477.

(32) Perrin, D. D.; Armarego, W. L. *Purification of Laboratory Chemicals*; Plenum Press: New York, 1988.

(33) Attached proton test: Patt, S.; Shoolery, J. N. *J. Magn. Reson.* 1982, 46, 535.

(34) Zweifel, G.; Whitney, C. C. *J. Am. Chem. Soc.* 1967, 89, 2753.

(35) Lemieux, R. U. *Adv. Carbohydr. Res.* 1954, 9, 1.




Figure 1.

of the ester moiety. When THF, a more polarizing solvent, was used as a cosolvent, the *threo* selectivity dropped, and remained relatively constant at 3:1 for the various esters. One plausible interpretation of this result is that the chelate ring of the initial complex is opened by THF, providing a greater percentage of the minor aluminoxy acetal. Another interpretation is that the increased polarity of the THF medium increases the rate of alkoxide elimination (solvent-separated ion-pair formation), favoring the S_N1 -like pathway. In either case, these results imply that the initial reduction step to form the chiral aluminoxy acetal center is stereochemically significant in the reduction/alkylation sequence, at least in the less polar solvents used in this study (e.g. CH_2Cl_2 , Et_2O , toluene, and hexane).

It is useful to compare the proposed transition states for our imine-chelated electrophiles with other closely related reactions (Figure 1). Duhamel's pioneering work with racemic N,N -dialkyl- α -amino aldehydes^{20b,g} showed that steric interference with the chelating-ability of the nitrogen lone pair (e.g. by N,N -dibenzyl substitution^{8t}) led to a Felkin-Ahn-type transition state I and *erythro* or *like* products, but that smaller groups (e.g. N,N -dimethyl substitution) permitted chelation control.^{20e} This was unfortunate, since one would like to have *removable* protection for nitrogen. Reetz showed that one could "tie back" the benzyl groups to favor the chelated transition state II and that this benzylic protection could be removed subsequent to the reaction.^{8t} Several groups^{8o-q} have now demonstrated that acyl-protected amines can provide the anionic chelated transition state III once the N-H proton has been removed to generate an imine-like nitrogen. This explains why such a trivial modification of the reaction conditions (e.g. $\text{H}_2\text{C}=\text{CHMgCl}$ vs $\text{H}_2\text{C}=\text{CHMgBr}$) can alter the course of the reaction so dramatically—the relative rate of deprotonation vs addition becomes extremely important, since deprotonation generates a chelating substrate from a substrate which normally undergoes Felkin-Ahn addition.²⁰ It is unclear whether Rapoport's 9-phenylfluorenyl-protected α -amino aldehydes¹⁰ undergo deprotonation in all cases prior to nucleophilic addition or not. The problem with these approaches is that they require high temperatures (-20 to 0 °C) to promote N-deprotonation, which is not conducive for the formation of stable chelates, and promotes deprotonation of the α -carbon (racemization) at the same time. The use of O'Donnell's Schiff base esters permits the chelation controlled addition of hydride (transition state IV) *without* the use of high temperatures. Although a portion of the desired *threo* product may arise from transition state V





Figure 2.

(S_N1 -like pathway), we feel that some of the product arises from transition state VI (S_N2 -like pathway).

It is impossible to either confirm or deny the possibility that the aluminoxy acetals can exist as tight ion-pairs VII or VIII (Figure 2) based on the available data. Indeed, the decrease in diastereoselectivity observed with coordinating solvents may be due to increased "leakage" between the two structures VII and VIII, rather than a change from the S_N2 -like to an S_N1 -like mechanism. Eclipsing interactions between the R group and the $\text{R}'\text{O}$ group should favor structure VIII if equilibration between the two ion-pairs were observed. The parallel *increase* in stereoselectivity with steric bulk of the ester presented in Scheme VII suggests that configurational equilibration (inversion) of the aluminoxy acetal via ion-pair rearrangement is *not* a major pathway at low temperatures and in the absence of THF, since one would expect the equilibrium VII \leftrightarrow VIII to shift to the right as the steric bulk of the $\text{R}'\text{O}$ group increases and result in *decreased* stereoselectivity.


Racemization Studies. Although some Boc-protected amino aldehyde derivatives show resistance to racemization (cf. Garner's *t*-Boc-protected cyclic aldehyde^{7e}), facile loss of optical activity in α -amino aldehyde derivatives is a general problem, especially under the basic conditions encountered during nucleophilic additions to aldehydes.^{8r,9-11} Comparison of the optical rotations of synthetic products 6b-d to authentic material showed less than 3% racemization. This result was confirmed by an analysis of Mosher amides derived from 6b and its enantiomer.³⁶ Similarly, known sphingosine triacetate 14 (vide infra) showed an optical rotation of 93–97%²⁸ of the expected value.^{7b,n} Carbohydrate-bearing glycosphingolipids

(36) The Mosher ester³⁷ i was prepared from synthetic amino alcohol 6b and compared with the diastereomeric Mosher ester ii prepared from the commercially available^{19b} enantiomer of 6b, (1*R*,2*R*)-(-)-norpseudoephedrine hydrochloride using ^1H NMR (250 MHz). No trace of ii could be detected in i. Authentic mixtures of i and ii were measured to check this method.



(37) (a) Hassner, A.; Alexanian, V. *Tetrahedron Lett.* 1978, 4475–8. (b) Garner, P.; Park, J. M. *J. Org. Chem.* 1987, 52, 2361–4.

(38) The ^1H NMR experiments were performed at 500 MHz. To a septum-sealed 5-mm NMR tube containing 7.0 mg of a 1:1 (w/w) mixture of $i\text{Bu}_2\text{AlH}$ and $i\text{Bu}_3\text{Al}$ (21 μmol) was added 1 g of CD_2Cl_2 (ampoule), and spectra were obtained at several temperatures. The changes observed in the spectra were reversible.^{23b} After the DIBAL/TRIBAL spectra were obtained, the sample was removed and frozen in liquid N_2 . After freezing, 5.5 mg of Schiff base 2a (21 μmol) in 1 g of CD_2Cl_2 was added via syringe, and the sample was quickly re-inserted into the NMR probe. As the sample thawed, the spectra in Scheme V were obtained.




^a (a) $\text{iBu}_2\text{AlH}\cdot\text{iBu}_3\text{Al}/\text{CH}_2/\text{Cl}_2/-78^\circ\text{C}$; (b) $\text{RLi}/\text{hexane}/-78^\circ\text{C} \rightarrow 0^\circ\text{C}$; (c) NaHCO_3 . * Isolated yields. *Threo/erythro* ratios were determined on the crude reaction mixtures by 250-MHz ^1H NMR.

prepared^{30d} from sphingosines 8a-d showed no evidence of diastereoisomerism.³⁹

Synthetic Applications: Sphingosines. *threo*-Sphingosines, their 1-*O*-glycosyl derivatives (psychosines), and ceramide derivatives are of interest as PKC inhibitors,⁶ and neuro-protective agents.^{6h} Toward these ends, we have synthesized a series of *threo*-sphingosines of various chain lengths. Reaction of the protected serine 4b with $\text{iBu}_2\text{AlH}\cdot\text{iBu}_3\text{Al}$ in CH_2Cl_2 at -78°C , followed by addition of a (*E*)-1-lithioalkene furnished a series of *threo*-sphingosine derivatives 8a-d (Scheme VIII). Reaction with the alanine derivative 2b provided the "1-deoxy-sphingosine" derivatives 9a-d in a similar fashion. The stereochemical outcome of these reactions run in $\text{CH}_2\text{Cl}_2/\text{hexanes}$ was superb, and SiO_2 flash chromatography²⁹ provided the diastereomerically pure Schiff bases in the yields indicated. Subsequent glycosylation showed that the sphingosines were enantiomerically pure as well.^{30c,39}

The diastereomeric ratios were determined by 250-MHz ^1H NMR spectroscopy of the crude reaction mixtures. The configuration of 9b was examined by hydrolysis of the N- and O-protection with acid (Scheme IX), followed by




^a (a) 1 N HCl; (b) $\text{O}=\text{C}(\text{imidazole})_2$; (c) $\text{PhN}=\text{C}=\text{O}$; (d) Ac_2O .

treatment of the resulting alcohol 10 with carbonyldiimidazole to furnish the oxazolidinone 11, which displayed a vicinal coupling constant of 7.6 Hz for the $-\text{OCH}-\text{HCN}-$ resonances. This is *not* consistent with the empirical rules for stereochemical assignment,²⁵ assuming that the configuration of 9b and 10 is indeed *threo*. Reaction of 8b with phenyl isocyanate provided the oxazolidine 12. The vicinal coupling constant for the $-\text{OCH}-\text{HCN}-$ resonances of 12 was also inconsistent with a *threo* assignment for 8b ($J = 7.7$ Hz). In light of this apparent discrepancy, Schiff base 8a was hydrolyzed to the amino diol 13, which was acylated to provide the triacetate 14 which was identical in every respect with the known compound.²⁸ Thus the *threo* assignment implicated by the norpseudoephedrine syntheses was confirmed unambiguously for sphingosines 8a-d and 9a-d.

In conclusion, we have developed a convenient one-pot, *threo*-selective synthesis of β -amino alcohols and sphingosines. The key features of this method are (1) availability and easy preparation of the crystalline Schiff base esters, (2) intermediacy of the nonenolizable (*nonracemizing*) aluminoxy acetals, and (3) high degree of *threo* stereoselectivity. That the aluminoxy acetals are indeed the reactive intermediates involved in this chemistry is implicated by their long life and stability at -78°C , their isolation as trapped monosilyl acetals, and the stereochemical effects of the ester moieties. The glycosylation

(39) Glycosylated *threo*-sphingosines^{30d} (e.g. iii) show no evidence of diastereoisomerism, indicating that significant racemization of the original chiral center has not occurred.



O-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2*S*,3*S*,4*E*)-1-*O*-benzoyl-2-[*N*-(diphenylmethylene)amino]-4-tridecen-3-ol (iii). ^1H NMR (CDCl_3): δ 8.00-7.90 (m, 2 H), 7.60-7.50 (m, 4 H), 7.40-7.10 (m, 9 H), 5.77 (dt, $J = 6.6, 15.4$ Hz, 1 H), 5.54 (dd, $J = 8.7, 15.4$ Hz, 1 H), 5.17-5.03 (m, 3 H), 4.49 (d, $J = 7.4$ Hz, 1 H), 4.40-4.21 (m, 4 H), 4.15-3.99 (m, 2 H), 3.61-3.56 (m, 1 H), 2.10-2.00 (m, 2 H), 2.09 (s, 3 H), 2.01 (s, 3 H), 1.94 (s, 3 H), 1.38 (s, 3 H), 1.25-1.15 (m, 12 H), 0.86 (t, $J = 7$ Hz, 3 H). ATP ^{13}C NMR (CDCl_3): δ 170.49, 170.22, 170.07, 169.28, 169.22, 165.98 (C=O's, C=N), 139.96, 136.26 (quaternary, aromatic), 135.90, 132.76 (HC-CH), 130.05 (quaternary, aromatic), 129.87, 129.45, 128.76, 128.32, 128.13, 127.75, 127.34 (aromatic), 100.06 (OCHO), 84.68 (OCH, allylic), 73.03 (AcOCH-3), 71.50 (OCH-5), 70.91 (AcOCH-2), 68.26 (AcOCH-4), 65.52 (BzOCH₂), 63.62 (=NCH), 62.00 (AcOCH₂-6), 32.24, 31.72, 29.30, 29.19, 29.10, 28.95, 22.51 (CH₂'s), 20.63, 20.43, 19.63 (CH₃C=O's), 13.99 (CH₃). $[\alpha]_D^{25} = -12.5^\circ$ ($c = 0.80, \text{CHCl}_3$).

of the Schiff base-protected sphingosines to provide psychosines and ceramides will be the subject of a forthcoming paper.^{30d}

Experimental Section

General Methods. All air- and moisture-sensitive reactions were performed under an argon atmosphere in flame-dried reaction flasks using standard schlenk methodology. All solvents were dried over standard drying agents³² and freshly distilled prior to use. For flash chromatography,²⁹ 400–230-mesh silica gel 60 (E. Merck No. 9385) was employed. All compounds described were >95% pure by ¹H and ¹³C NMR, and purity was confirmed by elemental analysis in several representative cases. The ¹H and ¹³C NMR spectra were obtained on a Bruker WM-250 spectrometer at 250 and 62.9 MHz, respectively. Chemical shifts are reported in δ vs Me₄Si in ¹H spectra and vs CDCl₃ in ¹³C spectra. All melting points were measured on a Hoover capillary melting point apparatus and are uncorrected. Infrared spectra were obtained on a Perkin-Elmer 1600 Series FT IR. Optical rotations were measured on a Randolph Research, AutoPol III polarimeter using the Na D line. Elemental analyses were performed by Desert Analytics, Tucson, AZ. Nominal and exact mass were obtained on a JEOL JMS-01SG-2 mass spectrometer.

Schiff Base Esters: Methyl *N*-(diphenylmethylene)-L-alaninate (2a). Diphenylketimine (7.0 g, 39 mmol) was added to a stirred solution of L-alanine methyl ester hydrochloride (4.33 g, 31.1 mmol) in CH₂Cl₂ (100 mL) and stirred overnight under argon.¹⁶ The reaction was poured into 1% NaHCO₃, washed (2 \times saturated NaHCO₃), and dried (K₂CO₃), and the solvent was removed under reduced pressure to provide crude product. Chromatography (40% EtOAc/hexanes) yielded 6.62 g of a white solid (25 mmol, 80%), mp 69–72 °C. ¹H NMR (CDCl₃): δ 7.70–7.50 (m, 2 H), 7.50–7.10 (m, 8 H), 4.18 (q, J = 6.7 Hz, 1 H), 3.71 (s, 3 H), 1.42 (d, J = 6.7 Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 173.13 (O=CO), 169.48 (C=N), 139.22, 135.96 (quaternary, aromatic), 130.11, 128.55, 128.46, 128.40, 127.84, 127.43 (CH, aromatic), 60.36 (OCH₃), 51.86 (=NCH), 19.00 (CH₃). [α]_D = -105.4° (c = 3.25, CHCl₃). IR (KBr): 1748.7, 1629.0, 1448.2, 1448.0, 1368.2, 1281.4, 1196.3, 1071.6, 712.0 cm⁻¹.

Ethyl *N*-(Diphenylmethylene)-L-alaninate (2b). Reaction as in 2a. Recrystallization (10% EtOAc/hexanes) provided pure product as a white solid (12.97 g, 46.2 mmol, 85%), mp 52–53 °C. ¹H NMR (CDCl₃): δ 7.80–7.10 (m, 10 H), 4.16 (m, 3 H), 1.42 (d, J = 6.7 Hz, 3 H), 1.25 (t, J = 7 Hz, 3 H). ¹³C NMR (CDCl₃): δ 172.46 (O=CO), 169.25 (C=N), 139.20, 136.00 (quaternary, aromatic), 129.96, 128.44, 128.30, 127.73, 127.35 (aromatic), 60.45 (OCH₂CH₃), 60.33 (=NCH), 18.87 (OCH₂CH₃), 13.90 (CH₃). IR (KBr): 1736.3, 1624.8, 1449.5, 1375.9, 1285.0, 1196.9, 1127.6, 787.1, 704.2. [α]_D = -90.0° (c = 2, CHCl₃).

Benzyl *N*-(Diphenylmethylene)-L-alaninate (2c). Diphenylketimine (1.98 g, 10.9 mmol) was added to a stirred solution of L-alanine benzyl ester hydrotosylate³⁰ (4.5 g, 12.8 mmol) in 50 mL of CH₂Cl₂ and stirred for 28 h at rt under argon.¹⁶ The mixture was then washed (0.1% NaHCO₃, 2 \times saturated NaHCO₃) and dried over K₂CO₃. The solvent was removed under reduced pressure and the resulting oil chromatographed (10% EtOAc/petroleum ether) to provide pure product as a colorless oil (3.0 g, 8.7 mmol, 80%). ¹H NMR (CDCl₃): δ 7.70–7.60 (m, 2 H), 7.4–7.25 (m, 11 H), 7.20–7.10 (m, 2 H), 5.19 (d, J = 12.5 Hz, 1 H), 5.12 (d, J = 12.5 Hz, 1 H), 4.21 (q, J = 6.7 Hz, 1 H), 1.45 (d, J = 6.7 Hz, 3 H). ¹³C NMR (CDCl₃): δ 172.49 (O=CO), 169.78 (C=N), 139.32, 136.08, 135.88 (quaternary, aromatic), 130.20, 128.64, 128.48, 128.34, 127.95, 127.81 (aromatic), 66.27 (OCH₂Ph), 60.53 (=NCH), 19.01 (CH₃). IR (neat): 1919.2, 1736.9, 1619.3, 1490.1, 1448.9, 1178.6 cm⁻¹. [α]_D = -65.7° (c = 1.3, CHCl₃).

Benzhydryl *N*-(Diphenylmethylene)-L-alaninate (2d). A solution of L-alanine benzhydryl ester hydrotosylate³¹ was reacted as in 2a. Chromatography (20% EtOAc/petroleum ether) provided pure product as a white solid in 81% yield (2.1 g, 5.3 mmol), mp 82–85 °C. ¹H NMR (CDCl₃): δ 7.70–7.60 (m, 2 H), 7.40 (m, 16 H), 7.20–7.10 (m, 2 H), 6.89 (s, 1 H), 4.25 (q, J = 6.7 Hz, 1 H), 1.48 (d, J = 6.7 Hz, 3 H). ¹³C NMR (CDCl₃): δ 171.14 (O=CO), 169.52 (C=N), 139.85, 135.82 (quaternary, aromatic), 130.05, 128.45, 128.27, 128.11, 127.74, 127.59, 127.44, 127.27, 126.88, 126.56 (aromatic), 76.64 (OCHPh₂), 60.64 (=NCH), 18.61 (CH₃). IR

(KBr): 3060.3, 2931.0, 2355.1, 1736.9, 1625.2, 1495.9, 1448.9, 1372.5, 1178.6, 1119.9 cm⁻¹. [α]_D = -46.5° (c = 2.2, CHCl₃).

Methyl *N*-(Diphenylmethylene)-L-phenylalaninate (3). Reaction as in 2a. Recrystallization (5% EtOAc/hexanes) provided pure product 3 (5.7 g, 16.6 mmol, 76%), mp 55–57 °C. ¹H NMR (CDCl₃): δ 7.60–7.00 (m, 13 H), 6.68 (d, J = 6 Hz, 2 H), 4.26 (dd, J = 4.3, 9.2 Hz, 1 H), 3.72 (s, 3 H), 3.28 (dd, J = 4.3, 13.2, 1 H), 3.17 (dd, J = 9.3, 13.2 Hz, 1 H). ¹³C NMR (CDCl₃): δ 172.17 (O=CO), 170.76 (C=N), 139.20, 137.74, 135.88 (quaternary, aromatic), 130.15, 129.70, 128.62, 128.18, 128.01, 127.85, 127.44, 126.17 (aromatic), 67.10 (=NCH), 52.07 (OCH₃), 39.63 (CH₂Ph). IR (KBr): 1743.3, 1625.9, 1445.9, 1286.0, 1200.7, 1169.0, 694.3 cm⁻¹. [α]_D = -285.7° (c = 2.3, CHCl₃).

Methyl *N*-(Diphenylmethylene)-L-serinate (4a). Reaction as in 2a. Recrystallization (EtOAc/hexanes) yielded 4a as 5.18 g of white crystals (18.3 mmol, 89%), mp 87–89 °C. ¹H NMR (CDCl₃): δ 7.70–7.20 (m, 10 H), 4.25 (t, J = 5.1 Hz, 0.3 H), 4.00–3.93 (m, 2.6 H), 3.76 (s, 2 H), 3.72 (s, 1 H), 3.14–3.10 (broad s, 0.7 H), 2.57 (dd, J = 5.8, 7.7 Hz, 0.3 H). ¹H NMR (benzene-*d*₆): δ 8.00–7.85 (m, 2 H), 7.80–7.70 (m, 2 H), 7.30–7.00 (m, 6 H), 4.44 (t, J = 5.3 Hz, 0.3 H), 4.20–4.10 (broad s, 0.5 H), 3.90–3.70 (m, 2 H), 4.50 (d, J = 6 Hz, 0.8 H), 3.33 (s, 0.7 H), 3.24 (s, 2 H), 2.60–2.50 (broad s, 0.3 H). ¹³C NMR (CDCl₃): δ 172.57 (O=CO), 142.78, 142.54 (quaternary, aromatic), 130.60, 128.78, 128.53, 128.13, 127.98, 127.78, 127.60, 126.51, 125.57 (CH aromatic), 101.07 (OCN), 67.29, 66.46, 64.15, 59.56, 52.41, 52.12. (Note: OCH₂, NCH, and OCH₃ resonances appear twice due to imine-oxazolidine tautomerism.) IR (KBr): 3500–3300, 1736.4, 1446.6, 1338.5, 1228.4, 750.9, 703.7, 630.6 cm⁻¹. MS (EI): 283 (M⁺), 224 (M - CO₂Me), 206 (M - H₂O - CO₂Me, 100). Anal. Calcd for C₁₇H₁₇NO₃: C (71.78), H (5.94), N (4.96). [α]_D = -136.14° (c = 8.5, CHCl₃).

Methyl *O*-(*tert*-Butyldimethylsilyl)-*N*-(diphenylmethylene)-L-serinate (4b). To a stirred solution of methyl *N*-(diphenylmethylene)-L-serinate (4a) (3.20 g, 11.3 mmol) in dry DMF (10 mL) were added imidazole (1.97 g, 28.9 mmol) and chloro-*tert*-butyldimethylsilane (2.76 g, 18.3 mmol). The mixture was stirred under argon for 24 h. The reaction mixture was poured into diethyl ether, washed with 1% NaHCO₃ (2 \times 15 mL), and dried (MgSO₄), and the solvent was removed under reduced pressure. Recrystallization (5% EtOAc/hexanes) yielded 4.10 g of white crystals (10.3 mmol, 92%), mp 57–59 °C. ¹H NMR (CDCl₃): δ 7.7–7.2 (m, 10 H), 4.30 (dd, J = 5.4, 7.6 Hz, 1 H), 4.11 (dd, J = 5.4, 9.8 Hz, 1 H), 3.92 (dd, J = 7.6, 9.8 Hz, 1 H), 3.68 (s, 3 H), 0.82 (s, 9 H), 0.00 (s, 3 H), -0.023 (s, 3 H). ¹³C NMR (CDCl₃): δ 171.28 (O=CO), 170.75 (C=N), 139.25, 135.94 (quaternary, aromatic), 130.08, 128.64, 128.41, 128.86, 128.17, 127.91 (aromatic), 67.48 (SiOCH₂), 64.43 (=NCH), 51.63 (OCH₃), 25.61 (C-CH₃), 18.02 (quaternary, SiC), -5.51, -5.62 (SiCH₃). IR (neat): 1725.2, 1625.1, 1285.6, 1125.3, 1074.6, 829.9, 779.2, 686.4 cm⁻¹. MS (70 eV): 397 (M⁺), 382 (M - CH₃), 340 (M - tBu, 100). [α]_D = -95.1° (c = 3.6, CHCl₃).

Synthesis of Norpseudoephedrine: Method A (2 equiv of DIBAL). The Schiff base esters (1.0 mmol) were dissolved in 10 mL of dry CH₂Cl₂ and cooled to -78 °C under an argon atmosphere. Two equivalents of diisobutylaluminum hydride (DIBAL) was then added (4.0 mL 0.5 M DIBAL in hexanes) over 90 min via syringe pump. The reactions were stirred an additional 15 min before 3 equiv of PhMgBr (1.0 mL 3.0 M PhMgBr in Et₂O) was added in one portion. The pale yellow solutions were stirred an additional 15 min at -78 °C and then warmed to room temperature. After the mixture was stirred at room temperature for 3 h, the reaction was quenched by pouring into 15 mL of saturated NaHCO₃. An additional 20 mL of CH₂Cl₂ was used in several portions to ensure complete transfer. These exact proportions of CH₂Cl₂:NaHCO₃ are recommended to avoid the formation of intractable emulsions. The aqueous layer was extracted with two additional 20-mL portions of CH₂Cl₂, and the combined organic layers were dried (K₂CO₃), filtered through Celite, and evaporated under reduced pressure. The products were purified via flash chromatography except for 5a which was recrystallized directly from CH₂Cl₂ or THF.

Method B (1:1 DIBAL-TRIBAL). The Schiff base esters (1.0 mmol) were dissolved in 10 mL of dry CH₂Cl₂ and cooled to -78 °C under an argon atmosphere. One equivalent of DIBAL-TRIBAL (1:1) was added (2.0 mL of 0.5 M solution in hexanes)

over 15 min via syringe pump. After addition was complete, 3 equiv of PhMgBr was added in one portion (1.0 mL of 3 M solution in Et₂O). The reactions were allowed to stir for 1 h at -78 °C followed by 1 h at rt and worked up as for method A above. (Solvent systems used for chromatography and yields for the two methods are listed in parentheses.)

***N*-(Diphenylmethylene)-1-phenylethanolamine (5a)** (white solid, 64% method A, 86% method B), mp 148–151 °C. ¹H NMR (CDCl₃): δ 7.7–7.6 (m, 2 H), 7.5–7.2 (m, 11 H), 7.1–7.0 (m, 2 H), 4.96 (dd, *J* = 3.8, 8.4 Hz, 1 H), 3.72 (s, 1 H), 3.62 (dd, *J* = 3.8, 14.4 Hz, 1 H), 3.47 (dd, *J* = 8.5, 14.4 Hz, 1 H). ¹³C NMR APT³³ (CDCl₃): 169.89 (N=C), 142.13 (quaternary, aromatic), 139.17, 136.49 (quaternary, aromatic), 130.31, 128.55, 128.39, 128.23, 128.08, 127.49, 127.40, 126.07, 125.85, (CH, aromatic), 101.02 (NCO), 79.00 (CHO), 73.71 (CHOH), 61.36 (CH₂N=), 55.00 (CH₂NH). (Note: oxazolidine-imine tautomerism.) IR (KBr): 3500–3100, 1617.9, 1490.2, 1444.5, 1316.7, 1093.8, 1060.4, 1026.6, 689.0, 542.3, 461.3 cm⁻¹. MS (70 eV): 301 (M⁺), 283 (M - H₂O), 194 (M - PhCHOH), 91 (C₇H₇, 100).

(1*S*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-1-phenylpropan-1-ol (5b) (oil, 15% EtOAc/petroleum ether, 54% method A, 78% method B). ¹H NMR (CDCl₃): δ 7.9–7.75 (m, 2 H), 7.7–7.55 (m, 2 H), 7.4–7.1 (m, 11 H), 4.42 (d, *J* = 8.5, Hz 1 H), 3.11 (dq, *J* = 6.4, 8.5 Hz, 1 H), 2.58–2.36 (broad s, 1 H), 1.22 (d, *J* = 6.4 Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): 145.50, 139.71 (quaternary, aromatic), 128.26, 128.21, 128.09, 127.65, 127.44, 127.15, 126.71, 126.30, 125.38 (CH, aromatic), 99.91 (OCN), 88.57 (OCH), 62.99 (=NCH), 15.58 (CH₃). IR (neat): 1726.4, 1490.0, 1450.8, 1235.9, 749.7, 698.9, 630.4 cm⁻¹. [α]_D = +198.9° (*c* = 1, CHCl₃).

(1*S*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-1,3-diphenylpropan-1-ol (5c) (oil, 10% EtOAc/petroleum ether, 69% method A, 75% method B). ¹H NMR (CDCl₃): δ 7.8–7.0 (m, 20 H), 5.88 (d, *J* = 7 Hz, 0.5 H), 4.86–4.81 (broad s, 0.25 H), 4.58 (d, *J* = 8.2 Hz, 0.75 H), 3.9–3.8 (broad s, 0.25 H), 3.63–3.56 (dt, *J* = 2.8, 6.9 Hz, 0.3 H), 3.48–3.40 (m, 0.75 H), 3.0 (d, *J* = 7 Hz, 0.5 H), 2.87 (dd, *J* = 4.2, 14.4 Hz, 0.75 H), 2.72 (dd, *J* = 8.8, 14.4 Hz, 0.75 H). ¹³C NMR (CDCl₃): δ 169.36 (N=C), 145.17, 145.09, 143.03, 139.71, 138.82, 138.47, 138.03 (quaternary, aromatic), 135.80, 129.89, 129.74, 129.65, 128.70, 128.10, 128.03, 127.92, 127.80, 127.48, 127.34, 127.27, 127.03, 126.98, 126.77, 126.66, 125.99, 125.95, 125.77, 125.68, 125.43 (aromatic), 99.78 (OCN), 85.63 (PhCHO), 75.64 (PhCHOH), 69.70 (=NCH), 67.82 (CHNH), 39.99 (CH₂Ph), 37.05 (CH₂Ph). (Note: oxazolidine-imine tautomerism.) IR (neat): 1601.0, 1495.2, 1451.3, 1222.0, 1028.7, 953.7, 743.8, 701.0 cm⁻¹. [α]_D = +68.4° (*c* = 2.4, CHCl₃).

(1*S*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-3-*O*-(*tert*-butyldimethylsilyl)-1-phenylpropane-1,3-diol (5d) (oil, 10% EtOAc/petroleum ether, 62% method A, 73% method B). ¹H NMR (CDCl₃): δ 7.9–7.75 (m, 2 H), 7.65–7.50 (m, 2 H), 7.45–7.15 (m, 11 H), 4.96 (d, *J* = 8.4 Hz, 1 H), 3.89 (dd, *J* = 3.2, 10.8 Hz, 1 H), 3.67 (dd, *J* = 1.6, 10.8 Hz, 1 H), 3.4–3.25 (broad s, 1 H), 3.20–3.14 (m, 1 H), 0.88 (s, 9 H), 0.11 (s, 3 H), 0.07 (s, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 145.58, 145.34, 140.46 (quaternary, aromatic), 128.32, 128.11, 128.06, 127.55, 127.49, 127.26, 126.85, 126.64, 125.71 (CH, aromatic), 100.09 (OCN), 81.86 (OCH), 68.33 (NCH), 59.13 (CH₂OSi), 25.75 (C-CH₃), 18.10 (quaternary, SiC), -5.5 (SiCH₃). IR (neat): 1662.2, 1600.5, 1490.4, 1450.0, 1253.7, 1089.6, 1065.1, 837.2, 777.6, 750.4, 699.2 cm⁻¹. [α]_D = +101.9° (*c* = 7.7, CHCl₃).

(1*S*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-1-ethoxy-1-siloxypropane (7a). Method C. To a stirred solution of ethyl *N*-(diphenylmethylene)-*L*-alaninate (2b) (283 mg, 1.0 mmol) in dry CH₂Cl₂ (4 mL) at -78 °C was added 2.4 mL of 0.5 M DIBAL-TRIBAL (1:1) in hexanes (1.2 mmol, 1.2 equiv) over 15 min. The resulting yellow solution was allowed to stir 72 h at -78 °C. TMS-imidazole (426 mg, 3 mmol) in CH₂Cl₂ (2 mL) was then added. The reaction was stirred for 2 h at -78 °C followed by an additional hour at rt. The yellow color persisted during the entire period at -78 °C but was discharged as the reaction mixture came to rt. The clear solution was quenched by pouring onto 15 mL of saturated NaHCO₃. The aqueous layer was washed with three 20-mL portions of CH₂Cl₂, and the combined organic layers were then dried (K₂CO₃) and evaporated under reduced pressure. The product was purified via flash chromatography²⁹ to yield 252 mg of an inseparable (6.5:1) mixture of 7a and 7b (0.71 mmol,

71%). ¹H NMR (CDCl₃): δ 7.65–7.10 (m, 10 H), 4.82 (d, *J* = 6.4 Hz, 1 H), 3.8–3.6 (m, 1 H), 3.5–3.3 (m, 2 H), 1.14 (t, *J* = 7 Hz, 3 H), 1.12 (d, *J* = 6.4 Hz, 3 H), 0.15 (s, 6 H), 0.09 (s, 3 H). ¹³C NMR APT³³ (CDCl₃): 7a: δ 167.22 (imine), 140.19, 137.02 (quaternary aromatics), 129.61, 129.55, 128.31, 128.23, 128.15, 128.04, 127.96, 127.84, 127.76, 127.34 (CH, aromatic), 101.41 (SiOCHO), 62.92 (CH₂O), 59.15 (CHN), 17.59, 15.28 (CH₃), 0.59 (SiCH₃). IR (neat): 1627.1, 1599.1, 1578.9, 1490.1, 1446.0, 1372.7, 1313.9, 1287.6, 1250.4, 1152.9, 1119.1, 1058.9, 1029.0, 952.9, 883.9, 840.3, 695.5, 647.9 cm⁻¹. [α]_D = +31.43° (*c* = 4.4, CHCl₃). High-resolution MS (CI-isobutane): M + 1 = 356.2035 (C₂₁H₃₀NSiO₂ = 356.2046).

(1*S*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-1-ethoxy-1-siloxypropane and (1*R*,2*S*)-2-[*N*-(Diphenylmethylene)amino]-1-ethoxy-1-siloxypropane (2:1 7a-7b Mixture). Method D (1:1:1 DIBAL-TRIBAL-PhLi). 1:1 DIBAL-TRIBAL (5 mL of 0.5 M in hexanes) was added to a flame-dried reaction vessel and chilled to -78 °C. PhLi (1.4 mL of 1.8 M in 7:3 cyclohexane/Et₂O) was added while stirring at -78 °C. The mixture was stirred for 1 h at -78 °C and then was allowed to warm to rt prior to use.

To a stirred solution of ethyl *N*-(diphenylmethylene)-*L*-alaninate, 2b (140 mg, 0.5 mmol), in dry CH₂Cl₂ (2 mL) at -78 °C was added 1.4 mL of 0.4 M DIBAL-TRIBAL-PhLi (1:1:1) in hexanes (0.56 mmol, 1.1 equiv) over 15 min. The resulting solution was allowed to stir for 1 h at -78 °C. TMS-imidazole (213 mg, 1.5 mmol) in CH₂Cl₂ (2 mL) was then added. The reaction was stirred for an additional hour at -78 °C followed by 1 h at rt. The reaction was quenched by pouring into 15 mL of saturated NaHCO₃. The aqueous layer was washed with three 20-mL portions of CH₂Cl₂, and the combined organic layers were then dried (K₂CO₃) and evaporated under reduced pressure. Analysis of the crude ¹³C NMR revealed the two possible diastereomeric products were formed in a 2:1 ratio. 7b. ¹³C NMR APT³³ (CDCl₃): δ 166.95 (imine), 139.81, 136.69 (quaternary aromatics), 129.61, 129.55, 128.31, 128.23, 128.15, 128.04, 127.96, 127.84, 127.76, 127.34 (CH, aromatic), 101.32 (SiOCHO), 67.68 (CH₂O), 62.56 (CHN), 17.45, 15.01 (CH₃), -0.52 (SiCH₃).

Protected Sphingosine Schiff Bases. The protected sphingosine derivatives 8a–d and 9a–d were synthesized from 4b and 2b using method A/method B as above, with the exception that (*E*)-lithioalkenes in hexane solution³¹ (prepared by I-Li exchange from the corresponding (*E*)-iodoalkenes)³⁴ were substituted for the PhMgBr/Et₂O. The reactions were worked up as before.

Cleavage of Schiff Base Protecting Groups. This was accomplished essentially as described by O'Donnell.¹⁶ The Schiff base-protected amino alcohols were dissolved in 1–3 mL of THF and 1–3 mL of 3% HCl. The solution was stirred at rt until TLC indicated that hydrolysis of the Schiff base was complete (usually 1–3 h). The reaction mixture was transferred to a separatory funnel and the aqueous layer washed with several volumes of CH₂Cl₂ to remove benzophenone. The aqueous layer was then made basic by addition of 2 N NaOH, and the product was extracted with several volumes of CH₂Cl₂. The combined organic layers were dried (K₂CO₃), and solvent was removed under reduced pressure. Isolated amino alcohols were obtained in approximately quantitative yield.

(2*S*,3*S*,4*E*)-2-[*N*-(Diphenylmethylene)amino]-1-*O*-(*tert*-butyldimethylsilyl)-4-octadecene-1,3-diol (8a) (oil, 5% EtOAc/petroleum ether, 78% method B). ¹H NMR (CDCl₃): δ 7.70–7.60 (m, 2 H), 7.50–7.40 (m, 2 H), 7.30–7.10 (m, 6 H), 5.64 (dt, *J* = 6.7, 15.2 Hz, 1 H), 5.24 (dd, *J* = 8.4, 15.2 Hz, 1 H), 4.28 (t, *J* = 8.4 Hz, 1 H), 3.84 (dd, *J* = 3.0, 10.6 Hz, 1 H), 3.60 (dd, *J* = 1.7, 10.6 Hz, 1 H), 3.10–3.00 (broad s, 1 H), 2.90–2.80 (m, 1 H), 2.10–1.90 (m, 2 H), 1.30–1.10 (broad s, 22 H), 0.90–0.80 (m, 12 H), 0.02 (s, 3 H), 0.00 (s, 3 H). ¹³C NMR APT³³ (CDCl₃): 145.55, 145.17 (quaternary aromatic), 134.99, 129.31 (HC=CH), 128.05, 127.84, 127.37, 127.08, 126.67, 125.72 (aromatic), 99.46 (OCN), 80.82 (OCH), 65.21 (OCH₂), 59.41 (CNH), 32.21, 31.90, 29.66, 29.60, 29.45, 29.34, 29.08 (CH₂), 25.78 (SiCCH₃), 22.66 (quaternary, SiC), 14.10 (CH₃), -5.49, -5.54 (SiCH₃). IR (neat): 2925.5, 1463.5, 1450.1, 1254.1, 1122.4, 968.4, 837.4, 770.0, 750.4, 701.7, 631.3, 532.2 cm⁻¹. [α]_D = +46.7° (*c* = 0.9, CHCl₃). **(2*S*,3*S*,4*E*)-2-Amino-4-octadecene-1,3-diol (*D*-threo-sphingosine) (13)** from 8a, mp 87–89 °C (lit. values^{7a,7b} mp 86–87 °C and 88.0–88.5 °C). ¹H NMR (CDCl₃): δ 5.75 (dt, *J* = 7, 15.1

H_z, 1 H), 5.46 (dd, $J = 6.2$, 15.1 Hz, 1 H), 3.99 (t, $J = 5.6$ Hz, 1 H), 3.71–3.65 (m, 1 H), 3.57–3.50 (m, 1 H), 2.79–2.75 (m, 1 H), 2.06–2.00 (m, 2 H), 1.80–1.50 (broad s, 4 H), 1.25 (broad s, 22 H), 0.88 (t, $J = 6.4$ Hz, 3 H). **D-threo-sphingosine triacetate (14)**⁷⁶ from 13. ¹H NMR (CDCl₃): δ 5.77 (dt, $J = 6.6$, 14.2 Hz, 1 H), 5.64 (d, $J = 9.7$ Hz, 1 H), 5.40 (m, 2 H), 4.43–4.37 (m, 1 H), 4.08 (dd, $J = 2$, 5.5 Hz, 2 H), 2.08–1.98 (m, 11 H, contains three singlets at 2.08, 2.07, 2.00), 1.25 (broad s, 22 H), 0.88 (t, $J = 6.6$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 170.54, 169.96, 169.75 (OC=O), 137.17, 123.99 (HC=CH), 72.94 (OCH), 62.97 (CH₂O), 50.72 (CNH), 32.15, 31.79, 29.54, 29.45, 29.30, 29.21, 29.00, 28.68 (CH₂), 23.10 (OAc), 22.57 (CH₂), 20.95, 20.63 (OAc), 13.98 (CH₃). IR (neat): 1747.1, 1653.8, 1540.3, 1456.8, 1371.1, 1231.8, 1045.4, 968.5 cm⁻¹. [α]_D = +8.2° ($c = 2.2$, CHCl₃) [lit. values^{7b,7n} +8.43°; +8.78° ($c = 1.2$, CHCl₃)].

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-1-O-(tert-butyl)dimethylsilyl-4-tridecene-1,3-diol (8b) (oil, 15% EtOAc/petroleum ether, 65% method B). ¹H NMR (CDCl₃): δ 7.80–7.70 (m, 2 H), 7.50–7.40 (m, 2 H), 7.30–7.10 (m, 6 H), 5.66 (dt, $J = 6.7$, 15.2 Hz, 1 H), 5.24 (dd, $J = 8.4$, 15.2 Hz, 1 H), 4.29 (t, $J = 8.3$ Hz, 1 H), 3.84 (dd, $J = 3.3$, 10.6 Hz, 1 H), 3.60 (dd, $J = 2.1$, 10.6 Hz, 1 H), 3.20–3.00 (broad s, 1 H), 2.95–2.85 (m, 1 H), 2.10–1.90 (m, 2 H), 1.40–1.15 (broad s, 12 H), 0.90–0.75 (m, 12 H), 0.02 (s, 3 H), 0.00 (s, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 145.49, 145.13 (quaternary, aromatic), 134.90, 129.31 (HC=CH), 127.99, 127.81, 127.34, 127.05, 126.64, 125.67 (aromatic), 99.44 (quaternary, OCN), 80.79 (OCH), 65.17 (CH₂O), 59.35 (NCH), 32.16, 31.81, 29.36, 29.21, 29.03 (CH₂), 25.74 (CH₃, tBu), 22.62, 18.13 (CH₂), 14.07 (CH₃), -5.52, -5.57 (SiCH₃). IR (neat): 2926.8, 1465.8, 1450.7, 1254.1, 1121.7, 1065.8, 1009.9, 968.2, 837.4, 778.0, 750.6, 701.1, 631.4 cm⁻¹. [α]_D = +41.9° ($c = 2.8$, CHCl₃). **(2S,3S,4E)-2-Amino-4-tridecene-1,3-diol from 8b**. Waxy solid. ¹H NMR (CDCl₃): δ 5.75 (dt, $J = 6.9$, 15.4 Hz, 1 H), 5.4 (dd, $J = 6.7$, 15.4 Hz, 1 H), 4.04 (t, $J = 6.1$ Hz, 1 H), 3.70 (dd, $J = 3.4$, 11 Hz, 1 H), 3.56 (dd, $J = 6.2$, 11 Hz, 1 H), 3.15–2.90 (broad s, 4 H), 2.90–2.80 (m, 1 H), 2.15–2.00 (m, 2 H), 1.50–1.20 (m, 12 H), 0.90 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR APT (CDCl₃): δ 134.05, 129.46 (HC=CH), 73.08 (OCH), 63.56 (CH₂O), 56.61 (CHN), 32.33, 31.83, 29.39, 29.24, 29.16, 22.60 (CH₂), 14.04 (CH₃). IR (neat): 3600–3200, 2925.0, 1458.3, 1379.9, 1253.9, 1028.0, 968.7, 853.3 cm⁻¹. [α]_D = -4.0° ($c = 0.63$, CHCl₃). MS (CI-isobutane): 230 (M + 1), 212 (M + 1 - H₂O). HRMS (CI-isobutane): M + 1 = 230.2129 (calcd for C₁₃H₂₈NO₂ (M + 1) 230.2120).

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-1-O-(tert-butyl)dimethylsilyl-4-decene-1,3-diol (8c) (oil, 10% EtOAc/petroleum ether, 40% method A, 60% method B). ¹H NMR (CDCl₃): δ 7.90–7.80 (m, 2 H), 7.80–7.70 (m, 2 H), 7.65–7.20 (m, 6 H), 5.74 (dt, $J = 6.7$, 15.2 Hz, 1 H), 5.32 (ddt, $J = 1.3$, 8.4, 15.2 Hz, 1 H), 4.36 (t, $J = 8.2$ Hz, 1 H), 3.91 (dd, $J = 3.0$, 10.7 Hz, 1 H), 3.68 (dd, $J = 1.6$, 10.7 Hz, 1 H), 3.21–3.10 (broad s, 1 H), 3.00–2.90 (m, 1 H), 2.15–2.00 (m, 2 H), 1.50–1.20 (m, 6 H), 0.90–0.80 (broad s, 12 H), 0.09 (s, 3 H), 0.08 (s, 3 H). ¹³C NMR (CDCl₃): δ 145.52, 135.08, 130.02, 129.23, 128.05, 127.84, 127.41, 127.08, 126.66, 125.70, 99.41, 80.82, 65.16, 59.36, 32.16, 31.27, 28.72, 25.89, 25.75, 22.45, 14.01, -5.57. IR (neat): 2928.9, 1448.5, 1251.7, 1089.1, 960.8, 832.4, 781.1, 695.5 cm⁻¹. [α]_D = +51.3° ($c = 0.9$, CHCl₃). **(2S,3S,4E)-2-Amino-4-decene-1,3-diol from 8c**. Waxy solid. ¹H NMR (CDCl₃): δ 5.76 (dt, $J = 6.7$, 15.4 Hz, 1 H), 5.46 (dd, $J = 6.7$, 15.4 Hz, 1 H), 3.98 (t, $J = 6.0$ Hz, 1 H), 3.69 (dd, $J = 4.3$, 10.7 Hz, 1 H), 3.54 (dd, $J = 6.2$, 10.7 Hz, 1 H), 2.82–2.76 (m, 1 H), 2.15–2.00 (m, 2 H), 2.10–1.75 (broad s, 4 H), 1.44–1.20 (m, 6 H), 0.88 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR (CDCl₃): δ 133.8, 129.8, 73.4, 64.0, 56.4, 32.2, 31.4, 28.8, 22.4, 13.9. IR (neat): 3500–3100, 2924.5, 1559.0, 1457.3, 1377.2, 968.8 cm⁻¹. [α]_D = -2.10° ($c = 1.1$, CHCl₃). MS (CI-isobutane): 188 (M + 1), 170 (M + 1 - H₂O). HRMS (CI-isobutane): M + 1 = 188.1672 (calcd for C₁₀H₂₂NO₂ (M + 1) 188.1651).

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-1-O-(tert-butyl)dimethylsilyl-4-nonene-1,3-diol (8d) (oil, 5% EtOAc/petroleum ether, 60% method B). ¹H NMR (CDCl₃): δ 7.75–7.65 (m, 2 H), 7.50–7.40 (m, 2 H), 7.30–7.10 (m, 6 H), 5.67 (dt, $J = 6.8$, 15.3 Hz, 1 H), 5.25 (ddt, $J = 1.3$, 7.1, 15.3 Hz, 1 H), 4.30 (t, $J = 8.3$ Hz, 1 H), 3.85 (dd, $J = 3.3$, 10.6 Hz, 1 H), 3.6 (dd, $J = 2.1$, 10.6 Hz, 1 H), 3.12–3.00 (broad s, 1 H), 2.94–2.89 (m, 1 H), 2.03–2.00 (m, 2 H), 1.40–1.20 (m, 4 H), 0.90–0.80 (m, 12 H), 0.03 (s, 3 H), 0.02 (s, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 145.47, 145.12

(quaternary, aromatic), 134.89, 129.21 (HC=CH), 128.15, 127.97, 127.92, 127.78, 127.33, 127.03, 126.61, 125.65 (CH, aromatics), 99.39 (OCN), 80.77 (OCH), 65.13 (NCH), 59.34 (CH₂O), 31.18, 31.13 (CH₂), 25.70 (CH₃, tBu), 22.05 (CH₂), 18.11 (quaternary, tBu), 13.79 (CH₃), -5.56, -5.62 (SiCH₃). IR (neat): 2928.4, 1449.9, 1254.1, 1121.1, 969.3, 837.2, 777.1, 750.2, 701.7, 631.1 cm⁻¹. [α]_D = +55.5° ($c = 3.2$, CHCl₃). **(2S,3S,4E)-2-Amino-4-nonene-1,3-diol from 8d**, mp 68–71 °C. ¹H NMR (CDCl₃): δ 5.75 (ddt, $J = 1$, 6.8, 15.4 Hz, 1 H), 5.46 (ddt, $J = 1.3$, 6.8, 15.4 Hz, 1 H), 4.00 (t, $J = 6.0$ Hz, 1 H), 3.68 (dd, $J = 4.3$, 10.8 Hz, 1 H), 3.54 (dd, $J = 6.2$, 10.8 Hz, 1 H), 2.90–2.80 (m, 1 H), 2.34–2.15 (broad s, 4 H), 2.15–2.0 (m, 2 H), 1.45–1.20 (m, 4 H), 0.90 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 133.74, 129.71 (HC=CH), 73.54 (OCH), 64.25 (CH₂O), 56.33 (CNH), 31.87, 31.20, 22.11 (CH₂), 13.81 (CH₃). IR (KBr): 3600–3000, 2925.7, 1583.5, 1456.8, 1378.7, 1053.9, 1023.9, 969.5, 860.1, 583.1, 487.4 cm⁻¹. [α]_D = -5.2° ($c = 0.9$, CHCl₃). MS (CI-isobutane): 174 (M + 1), 156 (M + 1 - H₂O). HRMS (CI-isobutane): M + 1 = 174.1492 (calcd for C₉H₂₀NO₂ (M + 1) 174.1494). Anal. Calcd: C, 62.43; H, 10.98; N, 8.09. Found: C, 62.38; H, 11.17; N, 8.07.

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-4-octadecene-3-ol (9a) (oil, 10% EtOAc/petroleum ether, 78% method B). ¹H NMR (CDCl₃): δ 7.75–7.65 (m, 2 H), 7.60–7.50 (m, 2 H), 7.30–7.10 (m, 6 H), 5.71 (dt, $J = 6.9$, 15.2 Hz, 1 H), 5.28 (dd, $J = 8.2$, 15.3 Hz, 1 H), 3.83 (t, $J = 8.3$ Hz, 1 H), 2.94 (dq, $J = 6.4$, 8.3 Hz, 1 H), 2.40–2.20 (broad s, 1 H), 2.03–1.96 (m, 2 H), 1.25 (broad s, 22 H), 1.18 (d, $J = 6.4$ Hz, 3 H), 0.88 (t, $J = 6.6$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 145.80, 145.31 (quaternary, aromatic), 134.91, 129.93 (HC=CH), 128.69, 128.30, 128.08, 127.83, 127.61, 127.27, 126.92, 126.21, 125.36 (aromatic), 99.22 (OCN), 87.28 (OCH), 59.52 (CNH), 32.18, 31.85, 29.60, 29.40, 29.30, 29.02, 22.61 (CH₂), 15.77 (1-CH₃), 14.06 (18-CH₃). IR (neat): 2923.9, 2852.9, 1489.1, 1450.2, 1378.1, 1232.6, 1067.3, 1029.3, 966.8, 749.2, 702.0 cm⁻¹. [α]_D = +75.8° ($c = 2.7$, CHCl₃). **(2S,3S,4E)-2-Amino-4-octadecene-3-ol from 9a**, mp 67–70 °C. ¹H NMR (CDCl₃): δ 5.72 (dd, $J = 6.7$, 15.4 Hz, 1 H), 5.40 (dd, $J = 7.3$, 15.4 Hz, 1 H), 3.67 (t, $J = 7.3$ Hz, 1 H), 2.81–2.7 (m, 1 H), 2.7–2.5 (broad s, 3 H), 2.10–2.00 (m, 2 H), 1.26 (broad s, 22 H), 1.06 (d, $J = 6.5$ Hz, 3 H), 0.88 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 133.69, 130.44 (HC=CH), 77.36 (OCH), 51.33 (CNH), 32.28, 31.84, 29.59, 29.41, 29.28, 29.13, 22.60 (CH₂), 20.18, 14.03 (CH₃). IR (KBr): 3500–3300, 3344.4, 3277.8, 2922.2, 2855.6, 1466.7, 1450.0, 1372.2, 1094.4, 1038.9, 961.1 cm⁻¹. Anal. Calcd for C₁₈H₃₇NO: C (76.32), H (13.07), N (4.95). Found: C (74.83), H (13.31), N (5.26). [α]_D = +9.7° ($c = 1.1$, CHCl₃).

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-4-tridecene-3-ol (9b) (oil, 10% EtOAc/petroleum ether, 71% method B). ¹H NMR (CDCl₃): δ 7.75–7.65 (m, 2 H), 7.60–7.50 (m, 2 H), 7.4–7.2 (m, 6 H), 5.71 (dt, $J = 6.9$, 15.2 Hz, 1 H), 5.31 (ddt, $J = 1.3$, 8.3, 15.2 Hz, 1 H), 3.83 (t, $J = 8.3$ Hz, 1 H), 3.00–2.90 (m, 1 H), 2.50–2.30 (broad s, 1 H), 2.10–1.90 (m, 2 H), 1.40–1.20 (m, 12 H), 1.18 (d, $J = 6.4$ Hz, 3 H), 0.88 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 145.78, 145.31 (quaternary, aromatic), 135.00 (HC=), 133.17 (aromatic), 129.96 (=CH), 128.67, 128.34, 128.11, 127.97, 127.84, 127.70, 127.61, 127.29, 126.95, 126.23, 125.37 (aromatic), 99.23 (NCO), 87.29 (OCH), 59.53 (NCH), 32.18, 31.80, 29.33, 29.19, 29.04, 28.98, 22.60 (CH₂), 15.78 (CH₃), 14.10 (CH₃). IR (neat): 3297.9, 2925.7, 1489.6, 1450.6, 1378.3, 1232.6, 1067.5, 1029.7, 967.7, 750.2, 702.8, 630.4 cm⁻¹. [α]_D = +79.5° ($c = 2.8$, CHCl₃). **(2S,3S,4E)-2-Amino-4-tridecene-3-ol (10) from 9b**. Waxy solid. ¹H NMR (CDCl₃): δ 5.72 (dt, $J = 6.7$, 15.4 Hz, 1 H), 5.41 (dt, $J = 7.0$, 15.4 Hz, 1 H), 3.65 (t, $J = 7.0$ Hz, 1 H), 2.90–2.70 (m, 1 H), 2.30–2.15 (broad s, 3 H), 2.10–2.00 (m, 2 H), 1.40–1.20 (m, 12 H), 1.10 (d, $J = 6.5$ Hz, 3 H), 0.88 (t, $J = 7.3$ Hz, 3 H). ¹³C NMR APT³³ (CDCl₃): δ 133.81, 130.34 (HC=CH), 77.32 (OCH), 51.33 (CNH), 32.27, 31.80, 29.36, 29.18, 29.12, 22.60 (CH₂), 20.20 (1-CH₃), 14.04 (13-CH₃). IR (neat): 3500–3100, 2924.5, 1559.0, 1457.3, 1377.2, 968.8 cm⁻¹. [α]_D = +7.36° ($c = 0.4$, CHCl₃). MS (CI-isobutane): 214 (M + 1), 196 (M + 1 - H₂O). HRMS (CI-isobutane): M + 1 = 214.2166 (calcd for C₁₃H₂₈NO (M + 1) 214.2171).

(2S,3S,4E)-2-[N-(Diphenylmethylene)amino]-4-decene-3-ol (9c) (oil, 10% EtOAc/hexanes, 45% method A, 72% method B). ¹H NMR (CDCl₃): δ 7.75–7.65 (m, 2 H), 7.60–7.50 (m, 2 H), 7.40–7.10 (m, 6 H), 5.71 (dt, $J = 6.8$, 15.2 Hz, 1 H), 5.30 (ddt, $J = 1.3$, 8.2, 15.2 Hz, 1 H), 3.83 (t, $J = 8.2$ Hz, 1 H), 3.00–2.90 (m, 1 H), 2.50–2.30 (broad s, 1 H), 2.10–1.90 (m, 2 H), 1.50–1.20 (m,

6 H), 1.18 (d, $J = 6.4$ Hz, 3 H), 0.87 (t, $J = 7$ Hz, 3 H). ^{13}C NMR (CDCl_3): δ 145.81, 135.61, 128.28, 128.20, 127.93, 127.37, 127.02, 126.29, 125.42, 99.29, 87.38, 59.59, 32.21, 31.33, 28.71, 22.45, 15.84, 14.01. IR (neat): 2926.2, 1450.4, 1232.9, 957.3, 750.0, 702.8, 630.2 cm^{-1} . $[\alpha]_{\text{D}} = +84.3^\circ$ ($c = 3$, CHCl_3). (2*S*,3*S*,4*E*)-2-Amino-4-decen-3-ol from 9c. Waxy solid. ^1H NMR (CDCl_3): δ 5.72 (dt, $J = 7.0$, 15.4 Hz, 1 H), 5.41 (ddt, $J = 1.2$, 7.0, 15.4 Hz, 1 H), 3.20 (t, $J = 7.0$ Hz, 1 H), 2.79–2.73 (m, 1 H), 2.03–2.00 (m, 2 H), 2.00–1.77 (broad s, 3 H), 1.44–1.20 (m, 6 H), 1.08 (d, $J = 6.3$ Hz, 3 H), 0.88 (t, $J = 6.8$ Hz, 3 H). ^{13}C NMR (CDCl_3): δ 133.9, 130.3, 77.4, 51.3, 32.2, 31.3, 28.7, 22.5, 20.5, 13.9. IR (neat): 3600–3200, 2925.4, 1581.5, 1456.1, 1378.0, 1094.1, 1037.5, 971.5, cm^{-1} . $[\alpha]_{\text{D}} = +4.6^\circ$ ($c = 0.9$, CHCl_3). MS (CI-isobutane): $M + 1$, 154 ($M + 1 - \text{H}_2\text{O}$). HRMS (CI-isobutane): $M + 1 = 172.1680$ (calcd for $\text{C}_{10}\text{H}_{22}\text{NO}$ ($M + 1$) 172.1701).

(2*S*,3*S*,4*E*)-2-[*N*-(Diphenylmethylene)amino]-4-nonen-3-ol (9d) (oil, 10% EtOAc/petroleum ether, 73% method B). ^1H NMR (CDCl_3): δ 7.90–7.80 (m, 2 H), 7.80–7.60 (m, 2 H), 7.60–7.20 (m, 6 H), 5.71 (dt, $J = 6.8$, 15.3 Hz, 1 H), 5.30 (dd, $J = 8.3$, 15.3 Hz, 1 H), 3.80 (t, $J = 8.3$ Hz, 1 H), 3.00–2.90 (m, 1 H), 2.50–2.20 (broad s, 1 H), 2.10–1.90 (m, 2 H), 1.40–1.20 (m, 4 H), 1.18 (d, $J = 6.3$ Hz, 3 H), 0.87 (t, $J = 7$ Hz, 3 H). ^{13}C NMR (CDCl_3): δ 135.19, 130.05 (OCH), 128.22, 127.93, 127.05, 126.31, 125.43, 99.25 (OCN), 87.41 (OCH), 59.59 (CNH), 31.95, 31.21, 22.18, 15.86, 13.90. IR (neat): 2957.8, 2926.2, 1726.8, 1662.3, 1450.0, 1276.5, 1067.7, 1029.1, 968.0, 749.8, 702.4, 630.0 cm^{-1} . $[\alpha]_{\text{D}} = +64.6^\circ$ ($c = 1.2$, CHCl_3). (2*S*,3*S*,4*E*)-2-Amino-4-nonen-3-ol from 9d. Oil. ^1H NMR (CDCl_3): δ 5.73 (ddt, $J = 0.8$, 6.7, 15.3 Hz, 1 H), 5.41 (ddt, $J = 1.4$, 7.0, 15.3 Hz, 1 H), 3.64 (t, $J = 6.7$ Hz, 1 H), 2.82–2.72 (m, 1 H), 2.10–2.03 (m, 5 H), 1.40–1.33 (m, 4 H), 1.21 (d, $J = 6.5$ Hz, 3 H), 0.90 (t, $J = 7$ Hz, 3 H). ^{13}C NMR APT³³ (CDCl_3): δ 133.61, 130.46 (HC=CH), 77.33 (OCH), 51.30 (CNH), 31.92, 31.24, 22.10 (CH_2), 20.08 (1- CH_3), 13.81 (9- CH_3). IR (neat): 3500–3000, 2926.4, 1582.7, 1453.8, 1378.3, 1141.1, 1093.4, 1037.5, 970.0, 865.8, 730.1 cm^{-1} . $[\alpha]_{\text{D}} = +10.9^\circ$ ($c = 3.4$, CHCl_3). MS (CI-isobutane): $M + 1$, 140 ($M + 1 - \text{H}_2\text{O}$). HRMS (CI-isobutane): $M + 1 = 158.1544$ (calcd for $\text{C}_9\text{H}_{20}\text{NO}$ ($M + 1$) 158.1545).

(4*S*,5*S*)-5-((*E*)-Dec-1-en-1-yl)-4-methyl-2-oxazolidinone (11). To a flame-dried reaction flask was added amino alcohol 10 (119 mg, 0.56 mmol), carbonyldiimidazole (118 mg, 0.73 mmol), and 2 mL of freshly distilled THF. The resulting solution was stirred for 2 h at rt. The THF was evaporated, the resulting residue was dissolved in Et_2O , washed (3×1 N HCl, $1 \times$ saturated NaHCO_3), and dried (K_2CO_3), and the solvent was removed under reduced pressure to provide crude material. Chromatography²⁹ (50% EtOAc/hexanes) provided 93 mg of pure product (70%, 0.39 mmol) as an oil. ^1H NMR (CDCl_3): δ 6.20 (broad s, 1 H), 5.85 (dd, $J = 6.8$, 15.4 Hz, 1 H), 5.50 (ddt, $J = 7.9$, 15.4, 1.4 Hz, 1 H), 4.43 (apparent t, $J = 7.6$ Hz, 1 H), 3.70–3.50 (m, 1 H),

2.10–2.00 (m, 2 H), 1.25 (broad s, 12 H), 0.88 (t, $J = 6.6$ Hz, 3 H). ^{13}C NMR APT³³ (CDCl_3): δ 159.31 (C=O), 137.75, 125.31 (HC=CH), 85.21 (OCH), 54.27 (CNH), 32.10, 31.80, 29.33, 29.17, 29.04, 28.63, 22.60 (CH_2), 19.22 (4- CH_3), 14.06 (CH_3). $[\alpha]_{\text{D}} = -29.9^\circ$ ($c = 1.6$, CHCl_3).

(4*S*,5*S*)-2,2-Diphenyl-5-((*E*)-dec-1-en-1-yl)-4-((*tert*-butyldimethylsiloxy)methyl)-*N*-(phenylcarbamoyl)oxazolidinone (12). (2*S*,3*S*,4*E*)-2-[*N*-(Diphenylmethylene)amino]-1-*O*-(*tert*-butyldimethylsilyl)-4-tridecene-1,3-diol (8b) (421 mg, 0.83 mmol) in dry pyridine (2 mL) was treated with $\text{PhN}=\text{C}=\text{O}$ (1.8 mmol, 2.2 equiv) and stirred at rt overnight. Pyridine and unreacted phenyl isocyanate were removed under reduced pressure, and chromatography²⁹ (20% EtOAc/petroleum ether) provided 409 mg of the pure product (78% yield, 0.65 mmol) as an oil. ^1H NMR (CDCl_3): δ 7.70–7.60 (m, 2 H), 7.50–7.20 (m, 9 H), 7.20–7.10 (m, 2 H), 6.90–6.80 (m, 2 H), 6.43 (broad s, 1 H), 5.83 (dt, $J = 6.4$, 15.4 Hz, 1 H), 5.66 (dd, $J = 7.1$, 15.4 Hz, 1 H), 4.25 (apparent t, $J = 7.7$ Hz, 1 H), 4.18–4.12 (m, 1 H), 3.92 (dd, $J = 3.9$, 10.5 Hz, 1 H), 3.84 (dd, $J = 4.7$, 10.5 Hz, 1 H), 2.10–2.0 (m, 2 H), 1.40–1.20 (broad s, 12 H), 0.90–0.80 (m, 12 H), 0.01 (s, 3 H), 0.00 (s, 3 H); ^{13}C NMR APT³³ (CDCl_3): δ 152.69 (C=O), 141.70, 140.58, 138.37 (quaternary, aromatic), 136.63, 128.52 (HC=CH), 128.46, 128.37, 128.23, 128.12, 126.70, 122.76, 119.49 (aromatic), 98.08 (OCN), 79.12 (OCH), 64.65 (HC-N), 62.65 (CH_2O), 32.19, 31.74, 29.30, 29.08, 28.69 (CH_2), 25.80 (SiCCH_3), 22.54 (SiCCH_3), 14.01 (CH_3), -5.40 (SiCH_3). IR (neat): 1673.6, 1596.9, 1528.7, 1441.9, 1332.1, 1249.5, 1102.7, 836.9, 751.6, 700.1 cm^{-1} . $[\alpha]_{\text{D}} = -14.1^\circ$ ($c = 1.2$, CHCl_3).

Acknowledgment. We would like to thank the University of Arizona for a Biomedical Research Support Grant (BRSG No. S07RR07002), the University of Arizona Foundation, and the American Cancer Society or an Institutional Cancer Research Grant Award. Acknowledgment is made to the donors of the Petroleum Research Fund, administered by the American Chemical Society, for partial support of this research. Ms. Lynn DeYoung would like to thank the National Science Foundation and the Howard Hughes Medical Institute for partial support of this work.

Supplementary Material Available: ^1H NMR (250 MHz) and ^{13}C NMR (62.5 MHz) spectra of compounds 2a–14 and amino alcohols (sphingosines) derived from the hydrolysis of compounds 8a–d and 9a–d (59 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

An Efficient, Regiocontrolled Synthesis of 5-Aryl-2-carbethoxypyrroles from 3-Aryl-3-chloropropeniminium Salts¹

John T. Gupton,* Dale A. Krolkowski, Richard H. Yu, and Phong Vu

Department of Chemistry, University of Central Florida, Orlando, Florida 32816

James A. Sikorski,* Maria L. Dahl, and Claude R. Jones

Monsanto Agricultural Co., New Products Division, A Unit of Monsanto Co., 700 Chesterfield Village Parkway, St. Louis, Missouri 63198

Received April 21, 1992

A variety of 3-aryl-3-chloropropeniminium salts react with α -amino acid esters under basic conditions to produce 2-carbethoxy-5-arylpyrroles in a regioselective manner. The overall process represents a short, efficient, and convergent synthesis of 2,5-disubstituted pyrroles, and azomethine ylides or azapentadienyl anions may be involved as intermediates.

We have recently reported² a short, convergent and regiocontrolled synthesis of 4-aryl-2-carbethoxypyrroles from

the condensation of 2-arylvinamidinium salts (1) with either glycine ethyl ester or sarcosine ethyl ester.